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1. INTRODUCTION 
 
Angelman syndrome (AS) and Prader-Willi syndrome (PWS), so-called sister 
syndromes, occupy an important place in the recent history of medical genetics 
and in contemporary research on human genetic disorders. These two clinically 
distinct disorders were among the first that were recognized to be caused by a 
small interstitial deletion of chromosomal material (Ledbetter et al., 1980; 
Ledbetter et al., 1981) when the technique of high-resolution banding was 
developed, and they both result from the deletion of the same chromosome 
region 15q11-13 (Kaplan et al., 1987; Magenis et al., 1987; Donlon, 1988). In 
AS the deletion is on the maternally inherited chromosome (Knoll et al., 1989), 
while PWS results from the deletion on the paternally inherited chromosome 
(Butler et al., 1986; Nicholls et al., 1989a). This phenomenon of parent-of-
origin difference in the expression of genes is presently known to be a 
consequence of genomic imprinting in this region (Nicholls et al., 1989b; Hall, 
1990; Williams et al., 1990). To date, in addition to the deletion, several diffe-
rent molecular mechanisms causing AS or PWS have been described, such as 
uniparental disomy (UPD) (Nicholls et al., 1989b; Knoll et al., 1991), im-
printing defects (ID) (Buiting et al., 1995) and mutations in a single gene, 
ubiquitin protein ligase E3A gene (UBE3A), in the case of AS (Kishino et al., 
1997; Matsuura et al., 1997; Sutcliffe et al., 1997). 
 In 1965, the first description of AS was reported by Harry Angelman, an 
English pediatrician. He described three severely mentally retarded children 
with similar facial features, absence of speech, paroxysms of laughter, abnormal 
puppet-like gait, epileptic seizures, and an abnormal EEG (Angelman, 1965). 
The first description of a PWS (-like) patient originates from John Langdon 
Haydon Down, who in 1864 reported a case that corresponds to the comprehen-
sive diagnostic criteria for PWS (Holm et al., 1993), using the term polysarcia, 
derived from the Greek roots poly (much) and sarca (flesh) (Down, 1864, cited 
in Ward, 1997). The syndrome was revived in 1956, when in the “Schweize-
rische Medizinische Wochenschrift” Andrea Prader, Alexis Labhart and 
Heinrich Willi from Zürich described nine patients with obesity, short stature, 
cryptorchidism and oligophrenia, usually preceded by severe amyotonia in 
infancy (Prader et al., 1956). The consensus diagnostic criteria were published 
in 1993 for PWS (Holm et al., 1993) and for AS in 1995 (Williams et al., 1995), 
and now these criteria serve as a basis for the initial clinical diagnosis of AS and 
PWS. Furthermore, the development of methylation-specific PCR (MS-PCR) 
assays to detect parent-specific DNA methylation imprint allows more rapid 
primary confirmation of these syndromes (Kubota et al., 1997; Zeschnigk et al., 
1997). 
 The occurrence of both syndromes has been considered to be comparable 
with an approximate frequency of 1 in 10,000 to 15,000 (Nicholls et al., 1998; 
Cassidy et al., 2000). However, these frequencies were deduced from a few 
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studies of either AS or PWS only (Burd et al., 1990; Åkefeldt et al., 1991; 
Clayton-Smith, 1993a; Ehara et al., 1995; Kyllerman, 1995; Petersen et al., 
1995; Buckley et al., 1998; Whittington et al., 2001), and any direct comparison 
between these surveys is weakened by differences in study populations and 
methods. Additionally, there have been some population-based studies looking 
for the etiology of mental retardation, with the results indicating that these 
syndromes are not equally prevalent (Hou et al., 1998; Strømme et al., 2000). 
 Several studies have emphasized the complexity of the early recognition of 
both syndromes. Apparently the clinical diagnosis of AS is difficult in the first 
two or three years of life because the clinical phenotype can be confused with 
other pathologies or due to the changing clinical features with age (Fryburg et 
al., 1991; Clayton-Smith, 1993c; Williams et al., 1995; Smith et al., 1996; 
Williams et al., 2006). The suspicion of PWS commonly rises in later childhood 
with the development of hyperphagia and obesity, while early neonatal/infantile 
phenotype of PWS have rarely been described in detail (Hoefnagel et al., 1967; 
Greenberg et al., 1987; Chitayat et al., 1989; Aughton and Cassidy, 1990; 
Miller et al., 1999). 
 Little is known of the causes of death in AS and only a few autopsy 
descriptions have been available in the literature (Jay et al., 1991; Kyriakides et 
al., 1992; Ishmael et al., 2002). In contrast, the sudden unexpected infant death 
(SUD) in PWS has recently emerged as a subject of discussion (Schrander-
Stumpel et al., 2004; Stevenson et al., 2004; Nagai et al., 2005). However, it is 
not known whether children and adults with PWS tend to die suddenly with 
greater frequency or have decreased life expectancy compared to the general 
population (Whittington et al., 2001; Nagai et al., 2005). 
 The objective of this study was to establish the livebirth and population 
prevalence of AS and PWS among individuals in Estonia born from 1984–2004, 
and to compare our results with studies performed in other populations. We also 
aimed to discover the clinical symptoms that facilitate early recognition of both 
syndromes, to describe in detail the clinical phenotype of our patients and, when 
possible, to investigate the causes of early death in patients with AS and PWS. 
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2. REVIEW OF THE LITERATURE 
 
2.1. History of AS and PWS 
 
AS and PWS are two clinically distinct disorders that result from the loss of 
expression of imprinted genes in the maternal and paternal chromosome region 
15q11-13 respectively. These syndromes have an important place in the 
contemporary history of human genetic disorders because of their unique and 
partially shared genetic basis. 
AS originates from England, when in 1965 the English pediatrician Harry 
Angelman (1965) collected three children with flat heads, jerky movements, 
protruding tongues and bouts of laughter under the term “puppets” because of 
their superficial resemblance to a marionette. All of these children shared 
common characteristic features such as horizontal depression in the occipital 
region of the skull, brachycephaly associated with microcephaly, primary optic 
atrophy, some degree of cerebral atrophy, frequent fits, a profound degree of 
mental retardation, paroxysms of laughter, ataxia and an ability to protrude the 
tongue to an unusual degree. In 1967 Bower and Jeavons described two similar 
patients and added the adjective “happy” to the “puppets” title (Bower and 
Jeavons, 1967). The first appearance in the literature under the name “Angel-
man’s syndrome” was in 1972, when Berg and Pakula described one new case 
and reviewed the previously described cases (Berg and Pakula, 1972). In 1982 
Williams and Frias suggested the eponym “Angelman syndrome” instead of 
“happy puppet syndrome” which was derisive and derogatory to the patients’ 
families (Williams and Frias, 1982). 
The first case report of a PWS (-like) patient probably originates from John 
Langdon Haydon Down, who in 1864 described a mentally subnormal woman 
of short stature, small hands and feet, extreme obesity and primary amenorrhea 
and called this condition “polysarcia” (Down, 1864, cited in Ward, 1997). In 
1956 Andrea Prader, Alexis Labhart and Heinrich Willi from Zürich described, 
in the “Schweizerische Medizinische Wochenschrift”, nine patients with 
obesity, short stature, cryptorchidism and oligophrenia, usually preceded by 
severe amyotonia in infancy (Prader et al., 1956). In the same year (1956), 
together with Guido Fanconi, they presented this syndrome at the 8th Inter-
national Congress of Pediatrics. Thereafter, Prader and Willi gave an updated 
overview of 14 cases at the 2nd International Congress on Mental Retardation in 
1961, adding to the syndrome’s description diminished fetal movements and a 
predisposition to diabetes in older age (Prader and Willi, 1961). They also 
suggested that the syndrome might have a genetic background, probably with a 
recessive mode of inheritance. However, there were no known cases of the 
occurrence of the syndrome in siblings or in more distant relatives. 
Initially, several different chromosomal abnormalities were associated with 
PWS, including a chromosomal translocation of two autosomes in the 13–15 
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group in a mentally deficient child with cryptorchidism (Bühler et al., 1963). 
The problem was solved when high-resolution chromosome analysis and 
multiple banding techniques applied to PWS patients showed de novo 
interstitial deletions of 15q11-13 (Ledbetter et al., 1980; Ledbetter et al., 1981; 
Ledbetter et al., 1982). The paternal origin of the deleted 15q was shown in all 
informative cases by Butler et al. in 1986, and later this exclusive trait was 
confirmed by molecular marker analysis (Nicholls et al., 1989a). Surprisingly, 
in 1987 the same 15q11-12 deletion was verified in three clinically different 
patients, one of them a patient with suspected Angelman syndrome (Kaplan et 
al., 1987). In the same year Magenis et al. (1987) described two unrelated 
females with AS having a similar deletion of the proximal long arm of 
chromosome 15 typical of PWS, suggesting a different chromosomal segment 
as a cause of the discrepancy. However, the deletions in both syndromes were 
indistinguishable using comparative molecular analysis (Donlon, 1988). The 
discrepancy was resolved when Knoll et al. (1989) demonstrated the maternal 
inheritance of the deleted chromosome 15 using restriction fragment length 
polymorphisms (RFLPs). This phenomenon of parent-of-origin difference in the 
expression of genes is now known as a consequence of genomic imprinting in 
this region (Nicholls et al., 1989b; Hall, 1990; Williams et al., 1990). To date, 
different molecular mechanisms causing AS or PWS have been described, such 
as uniparental disomy (UPD) (Nicholls et al., 1989b; Knoll et al., 1991), 
imprinting defects (ID) (Buiting et al., 1995), and mutations in a single gene, 
ubiquitin protein ligase E3A gene (UBE3A), in the case of AS (Kishino et al., 
1997; Matsuura et al., 1997; Sutcliffe et al., 1997). 
 
 
2.2. Consensus diagnostic criteria for AS and PWS 
 
2.2.1. AS 
 
The diagnosis of AS rests upon a characteristic combination of clinical features 
and genetic laboratory testing. In 1995, a consensus statement was published 
summarizing the salient clinical features of AS (Williams et al., 1995). 
Recently, an updated consensus for diagnostic criteria was released, which takes 
into consideration the scientific advances made in the last 10 years (Williams et 
al., 2006) (Table 1, Table 2). 
 A positive AS genetic test is strong evidence for AS, although a normal 
result does not rule out the diagnosis. In about 10–15% of individuals whose 
clinical presentation is characteristic of AS, genetic laboratory studies of 
chromosome 15 will be normal (no 15q11-13 deletion, UPD, ID or UBE3A 
abnormality) (Williams et al., 2006). This group of patients likely represents 
some combination of (i) as yet undetected lesions in chromosome 15q11-13 that 
affect the UBE3A locus; (ii) other novel genetic lesions that map elsewhere but 
affect expression of UBE3A; and (iii) incorrect diagnoses, representing 
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genocopies or phenocopies that do not perturb the expression of UBE3A (Jiang 
et al., 1999; Lossie et al., 2001; Williams et al., 2001). 
 
Table 1. Developmental history and laboratory findings in AS (Williams et al., 2006) 
 
Normal prenatal and birth history with normal head circumference and absence of 
major birth defects. Feeding difficulties may be present in the neonate and infant. 
Developmental delay evident by 6–12 months of age, sometimes associated with 
truncal hypotonus. Unsteady limb movements and/or increased smiling may be 
evident. 
Delayed but forward progression of development (no loss of skills). 
Normal metabolic, hematologic, and chemical laboratory profiles. 
Structurally normal brain using MRI or CT (may have mild cortical atrophy or 
dysmyelination). 
 
Table 2. Clinical characteristics of AS (Williams et al., 2006) 
 
Consistent (100%) Frequent (> 80%) Associated (20–80%) 
Developmental delay, 
functionally severe 
 
Movement or balance 
disorder, usually ataxia of 
gait, and/or tremulous 
movement of limbs 
 
Behavioral uniqueness: 
any combination of 
frequent laughter/ smiling; 
apparent happy demeanor; 
easily excitable 
personality, often with 
uplifted hand flapping 
movements; hypermotoric 
behavior 
 
Speech impairment, none 
or minimal use of words; 
receptive and non-verbal 
communication skills 
higher than verbal ones 
Delayed, dispropor-
tionate growth in 
head circumference, 
usually resulting in 
microcephaly by age 
2 
 
Seizures, onset 
usually <3 years of 
age 
 
Abnormal EEG, with 
a characteristic 
pattern, can precede 
clinical features 
Flat occiput 
Occipital groove 
Protruding tongue 
Tongue thrusting; suck/swallowing 
disorders 
Feeding problems and/or truncal hypotonia 
during infancy 
Prognathia 
Wide mouth, wide-spaced teeth 
Frequent drooling 
Excessive chewing/mouthing behaviors 
Strabismus 
Hypopigmented skin, light hair and eye 
color (compared to family), only in 
deletion cases 
Hyperactive lower extremity deep tendon 
reflexes 
Uplifted, flexed arm position especially 
during ambulation 
Increased sensitivity to heat 
Wide-based gait with pronated or valgus-
positioned ankles 
Abnormal sleep-wake cycle and decreased 
sleep 
Attraction to/fascination with water and 
crinkly items 
Abnormal food related behaviors 
Obesity (in the older child) 
Scoliosis 
Constipation 
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2.2.2. PWS 
 
The diagnosis of Prader-Willi syndrome is based on the characteristic clinical 
findings and a confirmation through cytogenetic and molecular studies. Con-
sensus diagnostic criteria for PWS were published in 1993 by five physicians, a 
nurse and a social worker, each of whom had many years of clinical experience 
with PWS (Holm et al., 1993). The diagnostic criteria are divided into three 
categories (major, minor and supportive), and are scored on a weighted point 
system. Major criteria are valued at one point and minor at one half point, 
whereas supportive criteria serve to increase the confidence, and are not 
included in the point system (Table 3). 
Holm et al. (1993) provided two scoring systems: for children aged 0 to 36 
months and for children aged 3 years to adults. In children 3 years of age and 
younger, five points are required for diagnosis, with four points from the major 
criteria (Table 3). For the older patients, a total score of eight points is required 
for diagnosis, with the major criteria comprising five or more points of the total 
score. 
 
 
Table 3. Clinical characteristics of PWS (Holm et al., 1993) 
 
Major criteria Minor criteria Supportive criteria 
Neonatal and infantile central 
hypotonia with poor suck 
 
Feeding problems in infancy 
with need for special feeding 
techniques, failure to thrive 
 
Excessive or rapid weight gain 
on weight-for-length charts in a 
short period of time after 12 
months of age, onset of obesity 
before 6 years of age 
 
Characteristic facial features 
 
Hypogonadism 
 
Global developmental delay, 
learning disabilities 
 
Hyperphagia/food foraging/ 
obsession with food 
 
Deletion 15q11-13 or any other 
cytogenetic or molecular 
abnormality in the PWSCR 
Decreased fetal movements or 
infantile lethargy or weak cry in 
infancy 
 
Characteristic behavior problems
 
Sleep disturbance or sleep apnea 
 
Short stature 
 
Hypopigmentalism 
 
Small hands/feet for height age 
 
Narrow hands with straight ulnar 
border 
 
Eye abnormalities 
 
Thick viscous saliva 
 
Speech articulation defects 
 
Skin picking 
High pain threshold 
 
Decreased vomiting 
 
Temperature instability in 
infancy 
 
Scoliosis and/or kyphosis 
 
Early adrenarche 
 
Osteoporosis 
 
Unusual skill with jigsaw 
puzzles 
 
Normal neuromuscular 
studies 
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2.3. Epidemiology of AS and PWS 
 
The occurrence of both syndromes has been considered to be similar, with an 
approximate frequency of 1 in 10,000 to 15,000 (Nicholls et al., 1998; Cassidy 
et al., 2000). However, these frequencies have been deduced from a few studies 
of either AS or PWS only (Table 4), and any direct comparison between these 
surveys is weakened by differences in study populations and methods. Additio-
nally, there have been some population-based studies that examine for the 
etiology of mental retardation with results leading to a different conclusion — 
these syndromes are not equally prevalent (Hou et al., 1998; Strømme et al., 
2000). 
 
 
Table 4. Studies on AS and PWS 
 
Author Estimated 
character 
Study population Period Number of 
cases/ 
confirmed 
diagnoses 
Data 
AS      
Clayton-Smith and 
Pembrey, 1992 
Incidence 1:20,000 
Clayton-Smith, 
1993a 
Population 
prevalence 
Mainly referrals 
to genetic consul-
tation, all ages 
 Unknown 
1:62,000 
Kyllerman, 1995 Prevalence 
rate 
6–13 y, epilepsy, 
MR 
1975–
1986 
4/2 1:12,000 
Petersen et al., 
1995 
Prevalence 
rate 
Neuropaediatric 
clinic 
1983–
1991 
5/5 1:10,000 
Buckley et al., 
1998 
Incidence Institutionalized, 
severe MR 
 11/3 1:20,000 
Thomson et al., 
2006a 
Birth 
prevalence 
Disability Servi-
ces Commission 
1953–
2003 
34/14 1:40,000 
AS and PWS      
Jacobsen et al., 
1998 
Population 
prevalence 
Institutionalized, 
moderate to pro-
found MR 
 285/4 1:20,000 
Vercesi et al., 1999 % among MR Boys with MR  256/0 0% 
PWS      
Burd et al., 1990 Population 
prevalence 
9–30 years old  17/- 1:16,062 
Åkefeldt et al., 
1991 
Population 
prevalence 
0–25 years old  11/5 12:100,000 
Birth 
incidence 
 1980–
1989 
11/4 1:15,060 Ehara et al., 1995 
Population 
prevalence 
0–15 years old  15/7 1:17,482 
 5
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Author Estimated 
character 
Study population Period Number of 
cases/ 
confirmed 
diagnoses 
Data 
Population 
prevalence 
1:52,000 Whittington et al., 
2001 
Birth 
incidence 
One UK Health 
Region, all ages 
 96/68 
1:29,000 
Smith et al., 2003a Birth 
prevalence 
Australian 
Paediatric Sur-
veillance Unit 
1998–
2000 
30/30 1:25,000 
Population 
prevalence 
 
 
78/78 
 
1:76,574 Vogels et al., 
2004a 
Birth 
incidence 
Flandria, referrals 
to four genetic 
centers, all ages 1993–
2000 
19/19 1:26,676 
Thomson et al., 
2006b 
Birth 
prevalence 
Disability 
Services 
Commission 
1953–
2003 
46/30 1:29,500 
 
 
 
2.3.1. Prevalence and incidence of AS 
 
The first published epidemiological data (Table 4) on AS estimated the 
incidence of AS to be around 1:20,000 (Clayton-Smith and Pembrey, 1992). In 
addition, Clayton-Smith (1993a) provided the minimum prevalence of AS in the 
UK as 1 in 62,000, mostly considering referrals to genetic consultation. 
Kyllerman (1995) performed a population-based study on epilepsy in 6- to 13-
year-old mentally retarded children born from 1975–86 in Göteborg, Sweden, 
and found four unrelated children with typical AS, two of whom had a 15q11-
13 deletion. The minimum prevalence rate was estimated to be 1:12,000. 
Petersen et al. (1995) reported on five AS children born between 1983 and 1991 
with the genetically confirmed 15q11-13 deletion, and calculated the prevalence 
rate for Denmark to be as high as 1:10,000. Buckley et al. (1998) calculated the 
incidence of AS in the general population to be approximately 1:20,000, 
considering 11 individuals with a clinical diagnosis of AS who were found in 
one long-term care facility among 225 mentally challenged residents. However, 
only three individuals had the deletion confirmed by FISH. The long-term 
population-based clinical study from Australia (Thomson et al., 2006a) revealed 
a birth prevalence for AS of 1:40,000 live births on the basis of data collected 
through the Disability Services Commission. Unfortunately the clinical diag-
nosis of AS was only confirmed by genetic testing in 14 persons out of 34. 
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2.3.2. Prevalence and incidence of PWS 
 
There are several studies on the epidemiology of PWS (Table 4). Burd et al. 
(1990) performed an extensive search among the population of the state of 
North Dakota, USA (population of 638,800 in 1990), and suggested a pre-
valence rate of 1:16,062 in the age range 9–30 years, equivalent to 1:38,395 in 
the entire population. This study was based on a clinical phenotype of PWS 
only and no specific number of cases with confirmed genetic diagnosis was 
provided. Åkefeldt et al. (1991) attempted to identify all cases of PWS among 
individuals aged up to 25 years in Skaraborg County, Sweden. They collected 
11 “definite cases”, five of which had the microdeletion 15q11-13. The 
calculated minimum prevalence for the 7–25 year age range was 13:100,000 
(1:7,700). After including borderline cases, the prevalence rose to 20:100,000 
(1:5,000) for this age group. In the San-in district in Japan, Ehara et al. (1995) 
collected 19 cases of PWS, and for the years 1980–1989 the birth incidence was 
1:15,060 live births, although of eleven patients, only four had the confirmed 
15q11-13 deletion. The population prevalence 1:17,482 was calculated con-
sidering 15 patients under 15 years old (1976–1990), seven of whom presented 
the 15q11-13 deletion. Whittington et al. (2001) counted all known cases in one 
UK Health Region and calculated a lower boundary for the population pre-
valence as 1:52,000, with the lower limit for birth incidence of 1:29,000. Of the 
96 individuals who were included, 68 had genetic confirmation of the 
syndrome. Smith et al. (2003a) estimated the birth prevalence of DNA-proven 
PWS. Thirty infants were reported to the Australian Paediatric Surveillance 
Unit between 1998 and 2000, indicating a prevalence of 4 per 100,000 live 
births or approximately 1:25,000 live births per annum. Vogels et al. (2004a) 
estimated the annual incidence of PWS to be 1:26,676 for the period 1993–
2000, and a population prevalence 1:76,574 considering all known cases of 
PWS confirmed by a DNA methylation test. In a more recent study from 
Australia based on 50 years of observation and 46 patients who were clinically 
diagnosed as having PWS, 30 had the genetically confirmed diagnosis (Thom-
son et al., 2006b). The birth prevalence for Western Australia was estimated as 
being 1:29,500. 
 
 
2.4. Genetic basis of AS and PWS 
 
2.4.1. General basis of AS and PWS 
 
AS and PWS are disorders linked to abnormalities in the inheritance of 
chromosome 15q11-13 (Ledbetter et al., 1980; Kaplan et al., 1987). The 15q11-
13 region is considered to have an increased liability toward rearrangement, 
especially recombination with telomeric and subtelomeric regions of other 
 20
autosomes. This may be related to the presence of repeat elements (palindro-
mes) flanking 15q12 that share homology with telomeric regions (Reeve et al., 
1993). Therefore the chromosome 15q11-13 region is meiotically unstable, with 
an unusual variety of cytogenetic rearrangements, including the AS and PWS 
deletions, frequent inverted duplications (Robinson et al., 1993a; Robinson et 
al., 1993b; Huang et al., 1997; Wandstrat et al., 1998), rare duplications and 
triplications (Clayton-Smith et al., 1993b; Schinzel et al., 1994; Cassidy et al., 
1996; Browne et al., 1997; Repetto et al., 1998), inversions (Webb et al., 1992), 
and balanced or unbalanced translocations (Butler 1990; Sun et al., 1996; Eliez 
et al., 1997; Windpassinger et al., 2003; Varela et al., 2004). 
 At the molecular level, 15q11-13 represents a very complex chromosomal 
region, and genes within a 2 Mb domain spanning half of 15q11-13 are 
imprinted, with expression of these genes dependent on the sex of the parent of 
origin. AS is associated with loss of expression of the maternal allele and PWS 
is associated with loss of expression of paternally derived alleles (Nicholls et 
al., 1998). This can happen through different mechanisms, which are described 
below in greater detail. 
 
 
2.4.2. Deletions of chromosome region 15q11-13 
 
The majority (65–75%) of AS and PWS cases are due to de novo large 
interstitial deletion (4–4.5 Mb) of 15q11-13 that includes a large cluster of 
imprinted genes (2–3 Mb) and a nonimprinted domain (1–2 Mb) (Nicholls et 
al., 1998). Interestingly, ≥ 95% of the deletion cases show the common deletion 
extents with three clustered breakpoints (BP): two alternative proximal clusters 
and a single distal BP region (Knoll et al., 1990; Kuwano et al., 1992; Christian 
et al., 1995; Amos-Landgraf et al., 1999; Christian et al., 1999). The proximal 
deletion BP commonly lies between D15S18 and the centromere (BP1), or 
between the D15S18 and D15S9 (BP2) loci, whereas the distal BP (BP3) has 
been mapped between the D15S12 and D15S24 loci (Knoll et al., 1990; 
Christian et al., 1995; Amos-Landgraf et al., 1999). AS/PWS deletions are cate-
gorized considering the common breakpoints, where the class I deletions extend 
from BP1 to BP3, and the class II deletions from BP2 to BP3. Analyses of the 
proximal extent of deletion in a large series of patients with AS or PWS 
confirmed that ~60% have class II and ~37% have class I deletions (Knoll et al., 
1990; Christian et al., 1995). However, despite sharing common deletion sizes, 
the critical regions (CR) and the shortest region of deletion overlaps (SRO) are 
different for AS and PWS (Buiting et al., 1995). These deletions define an 
imprinting centre (IC), which has two critical elements, the AS-SRO and the 
PWS-SRO. The SRO in patients with AS and an IC deletion (AS-SRO) is 880 
bp and maps 35 kb upstream of the exon 1 of SNURF-SNRPN (SNRPN up-
stream reading frame — small nuclear ribonucleoprotein polypeptide N) (Bui-
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ting et al., 1999). The PWS-SRO, described by Ohta et al. (1999b), is 4.1 kb 
and affects the SNURF-SNRPN promoter/exon 1 region. However, Bürger et al. 
(2002) reported a patient with a 570 kb deletion of UBE3A gene (ubiquitin 
protein ligase E3A, formely E6-AP) which was familial and was detected 
through allelic loss at microsatellite loci. The smallest described deletion for 
PWS was approximately 100–200 kb including genes SNRPN, PAR-5 (Prader-
Willi/ Angelman region 5) and PAR-7 (Prader-Willi/Angelman region 7) 
(Butler et al., 1996). 
 The common deletion sizes observed in AS and PWS are thought to be 
connected with regional genomic instability due to the presence of duplicated 
sequences (duplicons) at the proximal and distal regions at which patients show 
clustered breakpoints (Amos-Landgraf et al., 1999; Christian et al., 1999). A 
large part of these duplicons are derived from duplications of a large ancestral 
gene HERC2 (HECT domain and RCC1 domain protein 2) located at the distal 
PWS/AS breakpoint (Ji et al., 1999). A model to explain the generation of 
common AS and PWS deletions involves homologous misalignment and 
meiotic recombination between different HERC2-duplicons in proximal and 
distal 15q11-13 (Amos-Landgraf et al., 1999; Christian et al., 1999). 
 
 
2.4.3. Uniparental disomy of chromosome 15 
 
Approximately 2% of AS and 25% of PWS cases result from paternal or mater-
nal UPD 15q11-13 respectively (Malcolm et al., 1991; Nicholls et al., 1989b). 
 UPD represents the inheritance of both copies of part or an entire chromo-
some from a single parent, instead of the normal biparental transmission of the 
chromosome pair (Engel, 1980). UPD may occur both as heterodisomy (sequen-
ces from both homologues from the transmitting parent are present) and as 
isodisomy (two genetically identical segments from one parental homologue are 
present) (Nicholls and Knepper, 2001). There are multiple mechanisms for 
developing UPD: i) gamete complementation, when a germ cell by chance has 
the surplus of what lacks in the other; ii) monosomy duplication, through 
doubling of the lone chromosome of a monosomy; iii) trisomy rescue, through 
early mitotic loss of one of the three chromosomes (Engel, 1980; Engel, 2006). 
 In AS with a causative mechanism of paternal UPD, the likely origin is 
postzygotic mitotic duplication of the single sperm-derived chromosome, 
leading to isodisomic paternal UPD (monosomy rescue) (Robinson et al., 2000). 
In PWS most maternal UPD cases show maternal heterodisomy for chromo-
some 15 and are thought to result mainly from postzygotic correction of a 
trisomic embryo (Robinson et al., 1998; Robinson et al., 2000). The relative 
lack of paternal UPD15 cases compared with maternal UPD15 seems likely to 
be related to the lower rate of non-disjunction in male meiosis compared with 
female meiosis (Robinson et al., 1993c; Robinson et al., 2000). The probability 
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of maternal UPD due to a maternal non-disjunction event in meiosis I has been 
shown to increase exponentially with maternal age (Robinson et al., 1993d; 
Robinson et al., 1998; Robinson et al., 2000). Additionally, postzygotic errors 
in AS have been associated with maternal age, as the primary event is the 
maternal meiotic nondisjunction leading to a nullisomic egg fertilized by 
normal sperm and, later, duplication of the paternal chromosome in the zygote 
(Robinson et al., 1998; Robinson et al., 2000; Fridman et al., 2000). 
 
 
2.4.4. Imprinting defects of chromosome region 15q11-13 
 
Mutations in the imprinting process were first recognized in AS (Glenn et al., 
1993). However, in only a few patients, 1% in PWS and 2–4% in AS, is the 
disease caused by aberrant imprinting and gene silencing (Buiting et al., 2003). 
ID can occur without any DNA sequence changes (primary epimutations) or 
result from mutations in cis-regulatory elements or trans-acting factors (secon-
dary epimutations) (Horsthemke and Buiting, 2006). The identification of small 
deletions in a subgroup of patients with an imprinting defect has led to the 
definition of an IC that in cis regulates imprint resetting and maintenance in the 
whole domain (Sutcliffe et al., 1994; Buiting et al., 1995). Maternally inherited 
microdeletions affecting an 880-bp region 35 kb proximal to SNURF-SNRPN 
exon 1 (AS-SRO) impair the establishment of the maternal imprint and lead to 
AS. Some of these deletions have occurred de novo, but in most cases they have 
been inherited from the mother (Buiting et al., 1999; Ohta et al., 1999a). All of 
the microdeletions found in patients with PWS affect the SNURF-SNRPN 
promoter/exon 1 region (PWS-SRO 4.1 kb), and some of them have occurred de 
novo, but in most cases they have been inherited from the father (Ohta et al., 
1999b). PWS-SRO is probably not required for the establishment of the paternal 
imprint, but is necessary for the maintenance of the paternal methylation imprint 
during early embryonic development (El-Maarri et al., 2001). In contrast, the 
close proximity and/or the correct orientation of the AS-SRO and the PWS-
SRO are necessary to establish a maternal imprint (Buiting et al., 2001). 
However, IC deletions only occur in a small fraction of patients — the defect 
represents a primary epimutation in 92% of patients with AS and 85% of 
patients with PWS and ID (Buiting et al., 2003). Such epimutations can occur 
during imprint erasure in primordial germ cells, imprint establishment during 
later stages of gametogenesis, or imprint maintenance after fertilization. If it 
occurs in the germline, all of the patient’s cells are affected. If it occurs after 
fertilization, it often results in somatic mosaicism (Horsthemke and Buiting, 
2006). 
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2.4.5. UBE3A gene mutations 
 
UBE3A gene mutations occur in ~10–14% of AS cases (Lossie et al., 2001). 
Mutations can be identified in 11–44% of sporadic patients with normal 
methylation and ~75% of familial patients (Malzac et al., 1998; Fang et al., 
1999; Lossie et al., 2001; Rapakko et al., 2004). The UBE3A gene includes 16 
exons (coding region from exons 7–16) that span approximately 120 kb, with 
transcription oriented from telomere to centromere (Yamamoto et al., 1997; 
Kishino and Wagstaff, 1998). Point mutations have been found throughout the 
entire coding region, with clusters in exons 9 and 16, the latter of which 
contains a highly conserved domain that has been labeled “homologous to the 
E6-AP carboxyl terminus” or simply HECT (Malzac et al., 1998; Russo et al., 
2000; Rapakko et al., 2004). The catalytic cleft between the two lobes of the 
HECT domain is the site of many of the reported mutations (Huang et al., 
1999). Frameshift, nonsense, splice site mutations, and some missense 
mutations have been identified (Matsuura et al., 1997; Fung et al., 1998; Fang 
et al., 1999; Lossie et al., 2001; Rapakko et al., 2004). Several common 
polymorphisms have also been found within the UBE3A gene (Matsuura et al., 
1997; Malzac et al., 1998; Fang et al., 1999; Lossie et al., 2001; Rapakko et al., 
2004). The majority of mutations appear to form de novo, and only ~ 20% of 
mothers will carry the same mutation (Clayton-Smith and Laan, 2003). 
Mosaicism for UBE3A mutations has rarely been detected (Malzac et al., 1998; 
Rapakko et al., 2004), however, there have as yet been no patients with AS 
mosaic for maternal allele UBE3A mutations. With the exception of a few 
mutations that have been found in more than one patient, most mutations have 
been unique (Fung et al., 1998; Malzac et al., 1998; Baumer et al., 1999; Laan 
et al., 1999; Lossie et al., 2001; Rapakko et al., 2004). 
 
 
2.4.6. Structural chromosomal rearrangements involving 15q11-13 
 
Structural abnormalities of the chromosome region 15q11-13, such as inver-
sions and translocations, account for less than 1% of PWS and AS cases 
(Nicholls et al., 1998). Most of these rearrangements have been associated with 
a deletion of 15q11-13, uniparental disomy or an imprinting defect. Only a few 
translocations in PWS (Schulze et al., 1996; Sun et al., 1996; Conroy et al., 
1997; Kuslich et al., 1999; Wirth et al., 2001) and two inversions in AS without 
these changes have been described (Greger et al., 1997; Buiting et al., 2001). In 
all PWS cases the translocation was located within the SNURF-SNRPN locus, 
two of them had typical PWS phenotypes when the translocation disturbed the 
SNURF (Sun et al., 1996; Kuslich et al., 1999), yet three of them with atypical 
PWS phenotype had a balanced translocation with a BP distal to SNURF-
SNRPN, probably disrupting a cluster of multiple snoRNA genes (Schulze et 
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al., 1996; Conroy et al., 1997; Wirth et al., 2001). In the case of AS, a mater-
nally inherited paracentric inversion had one breakpoint within the UBE3A 
gene, inactivating the maternally active allele leading to the AS phenotype 
(Greger et al., 1997), and a familial inversion spanning approximately 1.5 Mb 
with one breakpoint inside the IC disrupting the IC and removing the AS-SRO 
from the PWS-SRO in the centre of the imprinted domain leading to the AS 
through the female germline (Buiting et al., 2001). 
 
 
2.4.7. Candidate genes for AS and PWS 
 
2.4.7.1. Candidate genes for AS 
 
In AS, the lesions of 15q11-13 are associated with the maternal chromosome, 
and therefore it was assumed that AS involves a maternally expressed gene(s). 
Based on the findings in patients with AS, an ubiquitin-protein ligase E3A gene, 
UBE3A, has been identified as the gene affected in AS (Kishino et al., 1997; 
Matsuura et al., 1997; Sutcliffe et al., 1997). There is another gene in 15q11-13 
that is preferentially expressed from the maternal chromosome in the brain and 
fibroblasts — aminophospholipid-transporting ATPase 10C, ATP10C (Herzing 
et al., 2001, Meguro et al., 2001). 
However, while the UBE3A gene was mapped to the AS/PWS region in as 
early as 1994, preliminary studies failed to show an imprinted expression using 
RT-PCR from fibroblasts and lymphoblasts of deletion PWS and AS patients, 
leading to the suggestion that UBE3A was an unlikely candidate locus for AS 
(Nakao et al., 1994). Only after the discovery of UBE3A mutations (Kishino et 
al., 1997; Matsuura et al., 1997) the gene was found to exhibit tissue-specific 
imprinting with maternal allele expression in the brain but not in the 
lymphocytes or fibroblasts (Rougeulle et al., 1997). In mice the imprinting was 
shown to be not only tissue specific, but also cell-type specific — the imprinted 
expression of UBE3A was preferentially restricted to the hippocampal and 
Purkinje neurons (Albrecht et al., 1997). 
UBE3A belongs to the family of proteins known as E3 ubiquitin-protein 
ligases, which are thought to play a key role in defining the substrate specificity 
of the ubiqutin-proteasome degradation system (Scheffner et al., 1993; 
Ciechanover, 2001). In the ubiquitin-proteasome system, the intracellular short-
lived regulatory proteins are marked by the attachment of multiubiquitin chains, 
which targets the selected proteins to the 26S proteasome for destruction (Vu 
and Sakamoto, 2000; Ciechanover, 2001). Several UBE3A mRNA subtypes 
encoding three protein isoforms differing at their N termini were reported 
(Rougeulle et al., 1997; Vu and Hoffman, 1997; Yamamoto et al., 1997; 
Kishino and Wagstaff, 1998). In addition to UBE3A function as an ubiquitin-
protein ligase, Nawaz et al. (1999) showed that the protein directly interacts 
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with and coactivates the transcriptional activity of the human progesterone 
receptor in a hormone-dependent manner. However, in the majority of AS 
patients examined, the ubiquitin-protein ligase function of UBE3A was 
defective, but the co-activation function was intact (Nawaz et al., 1999). 
Defective or absent E6-AP may result in the accumulation of substrate 
proteins, which are responsible for the disorder. However, in the case of AS it is 
not yet known what the targets of E6-AP are. Studies in a mouse model have 
shown that maternal deficiency heterozygotes (m-/p+) had a deficiency of 
context dependent learning (hippocampal-dependent learning deficit) and 
exhibited a deficit in long-term synaptic potentiation in the hippocampus in the 
absence of observable defects in baseline synaptic responses (Jiang et al., 1998). 
Recently a misregulation of phospho-calcium/calmodulin-dependent protein 
kinase II (CaMKII) in a maternal knockout Ube3a mouse model confirmed the 
role of hippocampal LTP involvement in the neurobehavioral deficits in a 
human learning disorder, AS (Weeber et al., 2003). 
 In 2001, ATP10C, showing preferential maternal expression in brain and 
fibroblasts, was mapped within ASCR 200 kb distal to the UBE3A locus 
(Herzing et al., 2001). ATP10C putatively functions as an aminophospholipid 
translocase likely to be involved in the asymmetric distribution of proteins in 
the cell membrane and therefore to be an important link in the maintenance of 
cell membrane integrity (Halleck et al., 1998; Meguro et al., 2001). Specific 
localization of the Atp10c transcript to mouse cerebellar granule cells, the 
hippocampus, and cells surrounding the corpus callosum (Halleck et al., 1999; 
Kashiwagi et al., 2003) is especially intriguing, since all of these areas have 
been suggested as being preferentially involved in autism (Lord et al., 2000) 
and overlap regions of imprinted Ube3a expression in mice (Albrecht et al., 
1997). 
 
 
2.4.7.2. Candidate genes for PWS 
 
PWS arises from the lack of expression of imprinted genes that are active only 
on the paternal chromosome (Nicholls et al., 1998). In contrast to AS, several 
such genes are known at the present time: SNURF-SNRPN, NDN, MAGEL2, 
MKRN3, and more than seventy C/D box snoRNA genes (Horsthemke and 
Buiting, 2006). Despite their similar expression patterns in the central nervous 
system (Lee et al., 2003) the contribution to PWS of any of these genes is 
unknown, and it is still a matter of debate whether PWS is caused by the loss of 
function of a single gene or of several genes (Horsthemke and Buiting, 2006). 
 Genetic evidence based on microdeletions in ID in humans and balanced 
translocation patients has implicated the central SNURF-SNRPN locus as a 
strong candidate for a major role in PWS (Buiting et al., 1995; Glenn et al., 
1996; Nicholls and Knepper, 2001). This exceedingly complex locus encodes at 
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least four functions: i) a cis-acting regulatory region (promoter/exon1) that is 
referred to as an IC (Sutcliffe et al., 1994; Buiting et al., 1995), ii) SNRPN 
(Buiting et al., 1993; Glenn et al., 1996), iii) SNURF (Gray et al., 1999), iv) a 
long (~460 kb) alternatively spliced RNA transcript that contains several 
families of small nucleolar RNAs (snoRNAs) (Gray et al., 1999; Cavaillé et al., 
2000; Horsthemke and Buiting, 2006). SmN is encoded by exons 4–10 of 
SNRPN and is a core spliceosomal protein involved in mRNA splicing in the 
brain, although mice carrying the specific gene ablation of the SmN-coding 
sequence (exons 5–7) were viable with no obvious phenotypical or histopatho-
logical defects (Yang et al., 1998). SNURF encodes a 71 amino acid protein that 
localizes in the nucleus. The potential functions of SNURF include regulation 
of SmN or of the imprinting process, the latter as a consequence of SNURF 
being the only protein-coding locus to overlap IC (Nicholls and Knepper, 2001). 
Nevertheless, ablation of the Snurf coding sequence (exon 2) in the absence of 
an IC defect has not revealed a phenotypic effect (Tsai et al., 1999). 
Nevertheless, because SNURF is disrupted by balanced translocations in only 
two patients with a classical PWS phenotype (Sun et al., 1996; Kuslich et al., 
1999), the role of this gene still needs further elucidation. 
 The NDN, encoding the MAGE family necdin protein, has been a particular 
focus of study, and it is proposed that nectin may act as a transcriptional 
repressor (Muscatelli et al., 2000; Lee et al., 2003; Lee et al., 2005). The related 
MAGE gene, MAGEL2, an intronless gene in proximity to the NDN locus, 
encodes a protein that is widely expressed in the central nervous system with 
unknown function (Boccaccio et al., 1999; Lee et al., 2000). The MKRN3 
intronless gene encodes a 507-amino acid protein with a RING (C3HC4) zinc 
finger motif and multiple C3H zinc finger motifs predicting a ribonucleoprotein 
function for the MKRN3 polypeptide (Jong et al., 1999). 
 Small nucleolar RNAs are a group of noncoding RNAs that function mainly 
as guides for the modification of ribosomal RNAs and small nuclear RNAs 
(Rogelj, 2006). Three families of human C/D box snoRNAs map to chromo-
some 15q11-13; they are brain specific and expressed only from the paternal 
allele (Cavaillé et al., 2000; de los Santos et al., 2000). However, the role of 
snoRNAs in PWS remains enigmatic. It was initially proposed that they could 
be crucial in developing PWS phenotype (Runte et al., 2001; Gallagher et al., 
2002). Further it was shown that the complete loss of the HBII-52 genes in one 
family members who carried the deletion on their paternal chromosome was not 
associated with an obvious clinical phenotype (Runte et al., 2005). In addition, 
Schule et al. (2005) described a 22-year-old male with a milder PWS phenotype 
and a de novo translocation t(4;15)(q27;q11.2), concluding that PWCR1/HBII-
85 snoRNAs probably play a major role in the PWS- phenotype. Also, based on 
their studies in mice carrying the large radiation-induced p(30PUb) deletion that 
includes the p locus, Ding et al. (2005) proposed that the lack of Pwcr1/MBII-
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85 snoRNA expression is the most likely cause for neonatal lethality in PWS 
model mice. 
 
 
2.4.8. Inheritance and risks of recurrence of AS and PWS 
 
The causal heterogeneity of AS and PWS complicates the evaluating of the risks 
of recurrence, and the correct genetic diagnosis plays a crucial role in 
counseling these families. 
 The most common genetic mechanism giving rise to AS and PWS (70–75% 
of patients) is an interstitial deletion of chromosome 15q11-13. Most deletions 
appear de novo and the risk of recurrence in these families is less than 1% 
(Horsthemke et al., 1996; Stalker and Williams, 1998). The incidence of 
complex structural chromosome abnormalities resulting in AS and PWS is 
relatively low, accounting for only 0.1% of cases (Chan et al., 1993; Nicholls et 
al., 1998). If the deletion identified in a proband is due to unbalanced trans-
location or chromosome rearrangement, the risk to the family depends on 
whether the rearrangement is inherited or arose de novo. Familial translocations 
involving 15q11-q13 can give rise to interstitial deletions causing PWS or AS, 
and these families need a case-specific evaluation of recurrence risks 
(Horsthemke et al., 1996; Stalker and Williams, 1998). Several patients have 
been reported in whom a supernumerary inverted duplication (15) was present 
in addition to an alteration leading to AS or PWS, and it was hypothesized that 
the presence of such a marker could increase the risk for other chromosome 
abnormalities (microdeletions, UPD) involving 15q11-q13 (Cheng et al., 1994; 
Spinner et al., 1995; Liehr et al., 2005). 
The occurrence of UPD is sporadic, and the risk of recurrence in families 
where AS or PWS are due to paternal or maternal UPD without any evidence of 
translocation is less than 1% (Stalker and Williams, 1998). In some cases 
UPD(15) arises in association with a Robertsonian translocation or a reciprocal 
translocation involving chromosome 15, and in families where the parent(s) of 
the affected child carries a balanced translocation, the recurrence risk is case-
specific (Smith et al., 1994; Tonk et al., 1996; Flori et al., 2004). 
To date, 32 deletions and one inversion in patients with AS or PWS and an 
ID on human chromosome 15 have been reported (Horsthemke and Buiting, 
2006). Some of the deletions have occurred de novo, but in most cases they 
have been inherited from the mother or father. Familial IC deletions are 
associated with a 50% recurrence risk. Other female (in AS) or male (in PWS) 
relatives who carry a known deletion in IC are also at a 50% risk of having an 
affected child, whereas male (AS) or female (PWS) relatives who carry the 
mutation are at risk of having affected grandchildren through their daughters 
(AS) and sons (PWS), who could inherit the mutation (Stalker and Williams, 
1998; Buiting et al., 2000; Horsthemke and Buiting, 2006). Since all ID without 
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IC deletions have been sporadic, they may represent a de novo defect in the 
imprinting process in 15q11-13 (Bürger et al., 1997; Buiting et al., 1998, 
Buiting et al., 2003). However, in 18 AS patients with a primary epimutation, 
the maternal chromosome carrying an incorrect paternal imprint was inherited 
from the maternal grandfather in 11 patients and from the paternal grandmother 
in seven patients. In contrast, in 19 informative PWS patients with a primary 
epimutation, the paternal chromosome carrying an incorrect maternal imprint 
was always derived from the paternal grandmother (Buiting et al., 2003). This 
bias was found to be highly significant (p=0.000002) and suggests that the 
incorrect imprint in the patients results from a failure of the paternal germline to 
erase the grandmaternal imprint (epigenetic inheritance). Although epigenetic 
inheritance of endogenous genes has not been reported in mammals, it is well 
known in other species (Chong and Whitelaw, 2004). Horsthemke and Buiting 
(2006) propose that it occurs at a low frequency in 15q11-13 and possibly also 
at other human loci. 
UBE3A mutations can be identified in 11–44% of sporadic patients and in ~ 
75% of familial patients with normal methylation (Malzac et al., 1998; Fang et 
al., 1999; Lossie et al., 2001; Rapakko et al., 2004). The majority of mutations 
occur de novo, and most of them have been unique (Malzac et al., 1998; Fang et 
al., 1999; Lossie et al., 2001; Rappako et al., 2004). If the mother carries the 
same mutation, the risk of recurrence is 50%, and female relatives of the mother 
who carry the same mutation also have a 50% risk of having a child with AS. 
The mother’s male relatives with the same mutation are not at risk of having an 
affected child, but are at risk of having affected grandchildren through their 
daughters, who could inherit the same defect from them. There are, however, 
several families where mothers have had more than one affected child despite 
having had a negative UBE3A analysis, and these mothers are likely to be 
gonadal mosaics (Clayton-Smith and Laan, 2003). In addition, Bürger et al. 
(2002) described a patient with a 570 bp deletion of UBE3A that was familial 
and detected through allelic loss at microsatellite loci only. 
There remain some patients (10–15%) with a clinical phenotype of AS with 
no identified chromosome 15 abnormality. This group is likely to be hetero-
geneous, and may include patients with other disorders (Williams et al., 2001; 
Clayton-Smith and Laan, 2003). Recently, Horsthemke and Buiting (2006) 
proposed that in some of these patients an ID cell line may have contributed to 
the brain and other tissues, but not to the blood system. 
 
 
2.4.9. Laboratory diagnostics of AS and PWS 
 
The diagnosis of AS and PWS rests upon a combination of clinical features and 
molecular genetic testing and/or cytogenetic analysis. 
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2.4.9.1. DNA methylation test 
 
Paternal-only expression of MKRN3, NDN and SNURF-SNRPN is associated with 
differential DNA methylation (Dittrich et al., 1992; Driscoll et al., 1992; Glenn et 
al., 1993). Whereas the promoter/exon 1 regions of these genes are unmethylated 
on the expressing paternal chromosome, the silent maternal alleles are 
methylated. Using restriction digests with the methylation-sensitive enzymes 
HpaII and HhaI and probing Southern blots with several genomic and 
complementary DNA probes, Driscoll et al. (1992) systematically scanned 
segments of 15q11-13 for DNA methylation differences between patients with 
AS and those with PWS. With the complementary DNA DN34, which maps in 
the proximal or central part of the AS/PWS CR (D15S9), they observed a marked 
difference in the methylation patterns of AS and PWS patients with deletions or 
UPD, and proposed that this phenomenon could serve as a molecular test for the 
diagnosis of these syndromes. If the DNA methylation test demonstrates only the 
methylated maternal allele, PWS is diagnosed; but when only unmethylated 
paternal allele is present, AS is diagnosed. Nowadays the development of 
methylation-specific PCR (MS-PCR) assays of the SNRPN region allows more 
rapid analysis of these syndromes (Kubota et al., 1997; Zeschnigk et al., 1997). 
The DNA methylation test could be the first step, but it does not distinguish 
patients with deletion, UPD or ID, and further testing of patients with abnormal 
parent-specific methylation imprint is essential. 
 
2.4.9.2. Genetic testing strategies for AS and PWS 
 
Table 5. Testing strategies for AS and PWS, proportions of diagnosed individuals 
 
Parent specific 
DNA methylation 
imprint 
Test method Abnormality detected 
Proportion of 
abnormality 
de novo deletion 
15q11-13 70% of AS & PWS High resolution 
cytogenetics; FISH Chromosomal 
rearrangement < 1% of AS & PWS 
2% of AS RFLP analysis; 
microsatellite or 
STR marker 
analysis 
UPD 
25% of PWS 
IC mutation <1% of AS & PWS 
Abnormal 
Sequence analysis Negative for IC 
mutation (ID) ~ 4% of AS & PWS 
Normal Sequence analysis (AS) 
Mutations in 
UBE3A gene 10–15% of AS 
Modified from Nicholls et al. (1998), Clayton-Smith and Laan (2003), and Horsthemke 
and Buiting (2006). 
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2.5. Clinical aspects of AS and PWS 
 
2.5.1. AS 
 
2.5.1.1. Early manifestations 
 
AS (Table 2) is characterized by four consistent (100%) clinical features: 
profound developmental delay, movement or balance disorder, severe speech 
impairment, and behavioral uniqueness with an inappropriate happy demeanor 
(Angelman, 1965; Williams et al., 1995; Williams et al., 2006). Unfortunately, 
AS is usually not suspected during the first year of life, but becomes a more 
frequent diagnostic consideration between 1 and 4 years of age (Fryburg et al., 
1991; Zori et al., 1992; Buntinx et al., 1995; Williams et al., 2006). There is, 
however, a growing experience in the early phenotype of AS if the diagnosis is 
given due consideration (Van Lierde et al., 1990; Yamada and Volpe, 1990; 
Fryburg et al., 1991; Bottani et al., 1994; Casara et al., 1995; Smith et al., 1996; 
Gillessen-Kaesbach et al., 1999; Moncla et al., 1999a; Moncla et al., 1999b; 
Williams et al., 2006). 
In general, individuals with AS have an uneventful prenatal and birth history 
with a birth weight, height and head circumference (HC) within the normal 
range (Fryburg et al., 1991; Clayton-Smith, 1993c; Williams et al., 1995; Smith 
et al., 1996; Williams et al., 2006). However, Clayton-Smith (1993c) found that 
babies with AS tended to be 200 g lighter in birth weight than their sibs. 
Fryburg et al. (1991) and Smith et al. (1996) noticed that birth weight and HC 
showed clustering below the 50th percentile in the case of AS newborns with 
15q11-13 deletion. Among 7 children with AS and an imprinting defect, HC at 
birth was average or between +3SD in 5 children (Gillessen-Kaesbach et al., 
1999). In spite of normal HC at birth, the growth of HC tends to stagnate and 
does not follow somatic growth, being remarkably microcephalic by 2 years of 
age (Fryburg et al., 1991; Smith et al., 1996). Babies with AS frequently 
demonstrate feeding difficulties, restlessness and poor sleep (Van Lierde et al., 
1990; Yamada and Volpe, 1990; Clayton-Smith, 1993c; Smith et al., 1996; 
Schulze at al., 2001). In addition, they seem to be hypotonic at birth (Smith et 
al., 1996; Gillessen-Kaesbach et al., 1999); however, mostly truncal hypotonia 
with brisk deep tendon reflexes has been described since 6 months of age, with 
uncoordinated movements involving the upper limbs in particular (Van Lierde 
et al., 1990; Yamada and Volpe, 1990; Fryburg et al., 1991; Clayton-Smith, 
1993c; Casara et al., 1995; Gillessen-Kaesbach et al., 1999; Schulze et al., 
2001). Excessive tongue thrusting and drooling with mainly happy disposition 
seem to be present by the same age (Van Lierde et al., 1990; Yamada and 
Volpe, 1990; Fryburg et al., 1991; Bottani et al., 1994; Schulze et al., 2001). 
Further motor development delays considerably — children with AS start to sit 
unsupported at on average 12 months of age, crawling begins at 22 months of 
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age, and most children are walking by the age of 5 years (Clayton-Smith, 
1993c; Buntinx et al., 1995; Smith et al., 1996). 
 
 
2.5.1.2. EEG findings 
 
The EEG features of AS appear to be sufficiently characteristic to help identify 
patients at an early age, before the clinical features become obvious (Williams 
et al., 1995; Williams et al., 2006). An abnormal EEG is often seen in patients 
with AS from at least 1 year of age, being uncommon before the age of 6 
months (Boyd et al., 1988; Casara et al., 1995; Boyd et al., 1997). The 
prevalence of EEG abnormalities in children and adults with AS is about 90% 
(Boyd et al., 1997; Laan et al., 1997). One or more of the following EEG 
abnormalities were seen in almost all patients with AS, irrespective of genotype: 
1) persistent rhythmic 4–6/s theta activity reaching more than 200 µV, often 
generalized and not associated with drowsiness, can be seen in AS patients 
under the age of 12 years (Boyd et al., 1988; Matsumoto et al., 1992; Boyd et 
al., 1997; Laan et al., 1997); 2) prolonged runs of rhythmic 2–3/s delta activity 
(200–500 µV) often more prominent over the frontal regions and sometimes 
associated with ill-defined spike/wave complexes (Boyd et al., 1988; 
Matsumoto et al., 1992; Casara et al., 1995; Laan et al., 1997; Minassian et al., 
1998); 3) bursts or runs of high amplitude (>200 µV) 3–4(5)/s rhythmic 
activity, maximal over the occipital region, sometimes containing spikes and 
sharp waves, and facilitated by, or only seen on eye closure, can be seen in 
young children (Boyd et al., 1988; Casara et al., 1995; Dan and Boyd, 2003). 
The latter could be the most reliable feature, but it is not easy to obtain 
voluntary eye closure in severely retarded and frequently hypermotoric AS 
patients (Laan et al., 1997). EEG abnormalities are much more prominent in AS 
patients with a deletion (97–100%), and not so pronounced in those with other 
genetic disturbances (Matsumoto et al., 1992; Laan et al., 1997; Minassian et 
al., 1998; Valente et al., 2005). A normal awake EEG background rhythm was 
reported in 72.2% of AS patients with UPD, ID and UBE3A gene mutations 
(Minassian et al., 1998). Nevertheless, Laan et al. (1999) found abnormal EEG 
patterns in 6 of 8 patients with UBE3A gene mutations, and Valente et al. 
(2005) observed suggestive EEG pattern for AS in 75% patients with UPD. 
 
 
2.5.1.3. Epilepsy 
 
The knowledge of features of epilepsy in AS is predominantly based on studies 
in patients determined by deletion, since this subgroup comprises ~ 70% of AS 
individuals (Matsumoto et al., 1992; Viani et al., 1995; Buoni et al., 1999). 
Epilepsy in AS is described as generalized, with mostly atypical absences and 
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myoclonic seizures, early onset and age-related refractoriness (Williams et al., 
1995; Laan et al., 1997; Valente et al., 2003; Williams et al., 2006). However, 
patients with AS may have different seizure types including epileptic spasms, 
atonic, astatic, tonic, tonic-clonic and even partial seizures (Matsumoto et al., 
1992; Clayton-Smith, 1993c; Casara et al., 1995; Viani et al., 1995; Guerrini et 
al., 1996; Laan et al., 1997). Seizures mostly start in infancy or early childhood, 
and the first seizure episode is frequently diagnosed during a febrile period 
(Casara et al., 1995; Viani et al., 1995; Laan et al., 1997). Non-convulsive 
status epilepticus seems relatively common and is probably underdiagnosed in 
AS (Matsumoto et al., 1992; Laan et al., 1997), though more overt myoclonic 
status epilepticus was recorded in nine out of 18 patients by Viani et al. (1995). 
In adulthood, a significant decrease in the incidence of epileptic seizures has 
been reported, and atypical absences, myoclonic seizures or a combination of 
the two were the most prominent seizure types (Matsumoto et al., 1992; 
Clayton-Smith, 1993c; Viani et al., 1995; Laan et al., 1997). The most effective 
AEDs in AS are valproic acid alone or in combination with clonazepam or other 
benzodiazepines, whereas carbamazepine sometimes had an adverse effect 
(Viani et al., 1995; Laan et al., 1997; Buoni et al., 1999). As a subgroup, 
patients with AS and UPD seem to have milder epilepsy and overall good 
response to AEDs (Fridman et al., 2000; Valente et al., 2005). In addition, the 
absence of EEG changes associated with stereotyped behaviors, particularly 
bursts of laughter, and even during head drops, argues against an epileptic 
origin of these specific manifestations of AS (Williams and Frias, 1982; Bjerre 
et al., 1984; Boyd et al., 1988; Sugimoto et al., 1992). Nevertheless, ventricular 
asystole during outbursts of laughter followed by syncope was observed in one 
AS patient (Vanagt et al., 2005), and vagal hypertonia was described in three 
children with AS, and one of them also had a ventricular asystole associated 
with bouts of laughter (Douchin et al., 2000). These findings emphasize the 
possibility of cerebral hypoxia induced non-epileptic convulsions in subjects 
with AS. 
 
 
2.5.1.4. CT/MRI findings 
 
Brain images using computed tomography (CT) or magnetic resonance imaging 
(MRI) show a structurally normal brain in most patients, but a mild cortical 
atrophy or dysmyelination may sometimes be present (Williams et al., 1995; 
Williams et al., 2006). Nevertheless, several case reports (Van Lierde et al., 
1990; Yamada and Volpe, 1990) and series of patients with AS (Fryburg et al., 
1991; Casara et al., 1995; Guerrini et al., 1996; Rubin et al., 1997; Saitoh et al., 
1997; Buoni et al., 1999) have frequently pointed out CT and/or MRI 
abnormalities, such as enlargement of the peri- and intracerebral spaces and, in 
particular, of the sylvian fissures, asymmetry of the lateral ventricules, 
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hypoplasia of the corpus callosum, and concomitant abnormalities in 
myelination. Furthermore, various rare brain malformations have been reported 
in patients with AS, including a vermian cyst (Incorpora et al., 1994), a split-
cord malformation (Mastroyianni and Kontopoulos, 2002), and an intracranial 
aneurysm (Meyer Witte et al., 2005). When compared with PWS children, AS 
children had a significantly larger proportion (75%) of anomalous fissures than 
the PWS children (12%) (Leonard et al., 1993). 
 
 
2.5.1.5. Causes of death/autopsies 
 
Little is known of the causes of death in AS, and only few autopsy descriptions 
were available in the literature (Jay et al., 1991; Kyriakides et al., 1992; Ishmael 
et al., 2002). Jay et al. (1991) presented findings of a 21-year-old woman with 
clinical AS, who died from a recurrent pneumonia complicated by pulmonary 
abscess. Her autopsy revealed an overall small brain and marked cerebellar 
atrophy with reduced γ-aminobutyric acid content in the cerebellar cortex, and a 
decreased dendritic arborization of the visual cortex. Another neuropathological 
study of a 34-month-old boy who died suddenly during sleep showed small 
temporal and frontal lobes with disorganized and irregular gyri; the occipital 
lobes appeared flattened but otherwise normal, as were the parietal lobes 
(Kyriakides et al., 1992). Microscopically, there was irregular distribution of 
neurons in layer 3, a few subcortical ectopic neurons in the cerebral white 
matter of the temporal and frontal lobes, and a single Purkinje cell heterotopia 
in the cerebellum. Ishmael et al. (2002) reported on a 9.6-year-old boy 
previously diagnosed with AS, whose fascination with water became deadly 
when he drown in a backyard wading pool. 
 
 
2.5.1.6. Phenotype-genotype correlation 
 
All of the genetic mechanisms in AS lead to a somewhat uniform clinical 
picture of severe to profound mental retardation, characteristic behaviors, and 
severe limitations in speech and language (Lossie et al., 2001; Clayton-Smith 
and Laan, 2003; Williams et al., 2006). While there are some clinical 
differences in genotype-phenotype correlation, great variability within each 
group has been described (Moncla et al., 1999a; Moncla et al., 1999b; Lossie et 
al., 2001; Peters et al., 2004; Varela et al., 2004): 
i)  Patients with AS resulting from large chromosome deletions appear to be 
more severely affected than patients from other genetic classes (Moncla et 
al., 1999b; Lossie et al., 2001; Varela et al., 2004; Williams et al., 2006), 
and the most striking difference was the observation that 50% of patients 
with deletion were non-ambulatory at 5 years of age (Lossie et al., 2001). 
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Also, the deletion group is the most severely affected by microcephaly, 
seizures, relative hypopigmentation and language impairment (Moncla et 
al., 1999b; Lossie et al., 2001; Williams et al., 2006). In addition, patients 
with a large deletion (BP1→BP3) tend to present the most severe phenotype 
considering motor and language development as compared to patients with 
a slightly smaller deletion (BP2→BP3) (Varela et al., 2004). 
ii)   Patients with AS and UPD have a better physical growth (less likely to have 
microcephaly, frequently with weight > 75th percentile), fewer or no 
seizures (late onset, infrequent seizures, good response to AEDs), less 
ataxia and hypopigmentation, less obvious dysmorphic facial features, and 
better cognitive skills (Bottani et al., 1994; Fridman et al., 2000; Varela et 
al., 2004; Valente et al., 2005). 
iii)  Patients with ID are less likely to have microcephaly, hypopigmentation or 
seizures, and show better growth, motor milestones and communication 
skills. Early childhood obesity is relatively common in this group (Saitoh et 
al., 1997; Gillessen-Kaesbach et al., 1999; Ohta et al., 1999a). An excep-
tionally mild phenotype is associated with an incomplete ID (Brockmann et 
al., 2002). 
iv)  The abilities of patients with UBE3A mutations fall somewhere in between 
those of the deletion group and the UPD group. They frequently have 
seizures and microcephaly, but no hypopigmentation, and their motor and 
communication skills are better than that of patients in the deletion group. 
Notably, this group shows a high incidence of early onset obesity (Moncla 
et al., 1999a; Lossie et al., 2001). 
 
 
2.5.1.7. Differential diagnosis 
 
A positive AS genetic test is strong evidence for AS, although a normal result 
does not exclude the diagnosis (Williams et al., 2006). In about 10–15% of 
individuals whose clinical presentation is characteristic of AS, genetic 
laboratory studies of chromosome 15 will be normal (no 15q11-13 deletion, 
UPD, ID, or UBE3A abnormality), indicating either yet undetected lesions in 
15q11-13 affecting function of the UBE3A gene, novel genetic lesions mapping 
elsewhere but affecting the expression of UBE3A, mutations in other genes with 
regulating effects (Jiang et al., 1999; Lossie et al., 2001) or a misdiagnosis of 
AS (Williams et al., 2001). 
 Infants with AS initially display global psychomotor delay and/or seizures, 
and therefore the differential diagnosis is broad and encompasses the 
chromosomal anomalies such as 22qter deletion (Precht et al., 1998), 15q11-13 
duplication (Clayton-Smith et al., 1993b; Repetto et al., 1998; Schroer et al., 
1998) and single gene disorders such as Rett syndrome with mutations in 
MECP2 (Ellaway et al., 1998; Watson et al., 2001), Mowat-Wilson syndrome 
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(Mowat et al., 2003), homocystinuria (Arn et al., 1998), and mutations in 
CDKL5, cyclin-dependent kinase-like 5, gene (Tao et al., 2004). In most cases, 
a group of heterogeneous disorders including cerebral palsy (Williams et al., 
2001), static encephalopathies (Williams et al., 2001), West and Lennox-
Gastaut syndrome (Boyd et al., 1988; Laan et al., 1997), pervasive develop-
mental disorders (Steffenburg et al., 1996; Williams et al., 2001), and mito-
chondrial encephalopathy (Nissenkorn et al., 2000) constitute the list for 
provisional investigations. 
 
 
2.5.2. PWS 
 
2.5.2.1. Early manifestations 
 
The diagnosis of PWS (Table 3) is difficult to establish in infancy. Usually the 
suspicion of PWS rises later, due to appearance of hyperphagia and obesity 
(Greenberg et al., 1987; Chitayat et al., 1989; Aughton and Cassidy, 1990). 
 The major clinical features in newborns include neonatal central hypotonia 
with poor suck, feeding problems, characteristic facial features and hypo-
gonadism (Holm et al., 1993). A variety of less frequent findings (minor and 
supportive criteria) (Table 3) include decreased fetal movements, infantile 
lethargy, weak cry, sleep disturbance or sleep apnea, and temperature instability 
in infancy (Holm et al., 1993). Several investigators have emphasized the 
complexity of recognizing a discrete facial dysmorphism and hypogenitalism, 
especially in female PWS newborns, and admit only the uniqueness of marked 
muscular hypotonia (Wharton and Bresnan, 1989; Miller et al., 1999; Gunay-
Aygun et al., 2001; Richer et al., 2001). Aughton and Cassidy (1990) have 
confirmed that in some cases dysmorphism may be observed in the neonatal 
period, but dysmorphic features are more commonly subtle or absent. In 
contrast, Chitayat et al. (1989) described four newborn patients with micro-
deletion, and stressed the importance of typical facial features, including a high 
forehead, frontal bossing, narrow bifrontal diameter, almond-shaped eyes, 
epicanthal folds, hypoplasia of the malar area, a high arched palate and minimal 
to no facial expression. Recent survey of 21 patients by Trifirò et al. (2003) 
demonstrated the same — more than half of patients displayed at least three 
different craniofacial features. In his short description of eight PWS patients, 
Stephenson (1980) found their faces sufficiently dysmorphic to order chromo-
some examination within the first weeks of life. In addition to faces, Chitayat et 
al. (1989) described patients’ fingers as very long, and Aughton and Cassidy 
(1990) also pointed out long and/or tapering fingers in two of their five patients. 
There are also several descriptions of hands in PWS newborns with flexed 
wrists and paralyzed distal parts (Aughton and Cassidy, 1990), a case report of 
distal arthrogryposis in PWS newborn (Denizot et al., 2004), and another case 
 36
where the patient tended to hold both thumbs adducted (Klinge et al., 2001). 
For newborns, Chitayat et al. (1989) also added cold extremities and intense 
skin mottling to the list of symptoms. Attention should be paid to the probable 
higher incidence of hip dysplasia in patients with PWS, as severe muscular 
hypotonia could disguise this problem, which requires early correction (Klinge 
et al., 2001; West and Ballock, 2004; Stevenson et al., 2004). 
 In 1989, Wharton and Bresnan described birth asphyxia in 23% of patients, 
but recently published survey by Trifirò et al. (2003) found neither perinatal 
asphyxia nor severe respiratory distress after birth in their group of patients with 
PWS. A number of studies have suggested a disposition to respiratory distress 
or apnoic spells in PWS (Chitayat et al., 1989; Saitoh et al., 1997; Yoshii et al., 
2002; Horsthemke et al., 2003; Denizot et al., 2004). 
 Feeding problems with subsequent failure to thrive, temperature instability 
and lethargy are common for PWS infants (Prader et al., 1956; Hoefnagel et al., 
1966; Chitayat et al., 1989; Butler, 1990; Holm et al., 1993). The psychomotor 
development delay causes the average onset of crawling to take place at 16 
months, walking at 28 months and talking at 39 months (Butler, 1990). Later, 
mostly between 2–4 years of age, an insatiable appetite develops, leading to 
excessive weight gain and the onset of obesity before 6 years of age (Butler, 
1990; Dimitropoulos et al., 2000). Early diagnosis of PWS could serve to 
prevent obesity if the child’s diet can be strictly controlled. However, children 
on an early diet tend to become shorter than children without diet regulations 
(Schmidt et al., 2001). Children with PWS frequently develop learning 
disabilities and speech articulation defects (Curfs et al., 1991; Roof et al., 
2000). Hypogonadism as a manifestation of genital hypoplasia is diagnosed 
soon after birth, especially in males, while an incomplete puberty and infertility 
develop in both sexes later in life (Holm et al., 1993). 
 
 
2.5.2.2. CT/MRI findings 
 
PWS has been viewed as a genetic human obesity syndrome with characteristic 
phenotypes, including gross hyperphagia, hypogonadism and growth hormone 
(GH) deficiency that indicate hypothalamic dysfunction (Prader et al., 1956; 
Holm et al., 1993; Swaab, 1997). However, there are only very few reports 
documenting peculiarities in the brain of PWS in respect to presumable 
hypothalamic dysfunction/deficiency or impaired central nervous system (CNS) 
development (Miller et al., 1996; Hashimoto et al., 1998; Klinge et al., 2001; 
Yoshii et al., 2002; Miller et al., 2006; Yamada et al., 2006). Miller et al. 
(1996) hypothesized that an MRI of the pituitary gland in PWS patients might 
reveal a measurable decrease in the size of the anterior pituitary gland, and that 
there might be an alteration in the posterior pituitary bright spot, which is a 
reflection of hypothalamic function and has been found to be absent in other 
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groups of patients (diabetes insipidus). All of their 15 study subjects with PWS 
had smaller average gland sizes, but the differences were too small to reach 
statistical significance. However, three patients (20%) demonstrated total 
absence of the posterior pituitary bright spot, and one patient showed an 
unusually small posterior pituitary bright spot. No data about the patients’ 
genetic background was provided (Miller et al., 1996). Hashimoto et al. (1998), 
using proton magnetic resonance spectroscopy (1H-MRS) in five patients with 
PWS, found that in the right parietal region the amount of N-acetylaspartate (an 
indicator of neuron function) was decreased. This finding could suggest a 
regional brain damage causative in the loss of cognitive functions. Yoshii et al. 
(2002) reported on a preterm girl (gestational age of 35 weeks) with PWS and 
deletion, whose MRI, performed at a corrected age of 40 weeks, showed a 
diffusely abnormal gyral folding pattern and multiple regions where the gray-
white matter junction was markedly irregular involving all lobes. Recently, 
Yamada et al. (2006), using diffusion tensor imaging based on a high-field MRI 
system, observed eight patients with PWS and altered diffusivity characteristics 
in the frontal white matter, the left dorsomedial thalamus, the posterior limb of 
the internal capsule, and the splenium of the corpus callosum, indicating 
probable developmental abnormalities in these brain areas. Also, three dimen-
sional MRI scans of twenty PWS individuals revealed ventriculomegaly in all, 
decreased volume of brain tissue in the parietal-occipital lobe in 50%, sylvian 
fissure polymicrogyria in 60%, and incomplete insular closure in 65% of PWS 
subjects (Miller et al., 2006). 
 
 
2.5.2.3. Causes of death/autopsies 
 
Individuals with PWS often develop life-threatening abnormalities such as 
severe hypotonia and feeding difficulties in infancy, dysregulation of 
temperature in young children, and massive obesity, diabetes mellitus, 
respiratory failure, and cor pulmonale in adolescents and/or adults (Holm et al., 
1993; Cassidy, 1997a; Smith et al., 2003b; Stevenson et al., 2004; Vogels et al., 
2004a; Nagai et al., 2005). However, it is not known whether children and 
adults with PWS tend to die suddenly with greater frequency and have 
decreased life expectancy than the general population (Whittington et al., 2001; 
Nagai et al., 2005). Recently introduced GH treatment and successively 
reported cases of sudden unexpected death (SUD) during a few months of 
treatment have raised the questions of whether the GH treatment is related to the 
SUD, and on the relative importance of extreme critical illnesses in PWS 
(Clericuzio et al., 1997; Schrander-Stumpel et al., 1998; Eiholzer et al., 2002; 
Nordmann et al., 2002; Smith et al., 2003b; Schrander-Stumpel et al., 2004; 
Stevenson et al., 2004; Van Vliet et al., 2004; Nagai et al., 2005). Infants under 
1 year of age without GH treatment tended to die suddenly during feeding 
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(hypoventilation and aspiration) or after a short febrile illness due to infection 
(bronchopneumonia, acute diarrhea, pneumonia, sepsis) (Hayashi et al., 1992; 
Schrander-Stumpel et al., 2004; Stevenson et al., 2004; Nagai et al., 2005). 
However, one 8-month-old boy receiving GH died during feeding, but the 
postmortem examination revealed bronchopneumonia (Nordmann et al., 2002). 
Infants up to 3 years of age without GH therapy mostly had a febrile illness 
associated with respiratory symptoms, diarrhea, aspiration or convulsion, 
although, when seen by a physician, the symptoms were not considered to be 
life-threatening and the death was unexpected; none of these children was obese 
(Schrander-Stumpel et al., 2004; Stevenson et al., 2004; Nagai et al., 2005). 
One 3-year-old with ongoing GH therapy died suddenly during sleep, although 
concomitant pneumonia was revealed on autopsy (Nagai et al., 2005). SUD 
among older children and adolescents not on GH therapy was seldom described, 
but all reported deceased patients receiving GH therapy were boys and had 
massive obesity (Nagai et al., 2005). 
So far only a few autopsies with a special interest in brain abnormalities 
have been reported. Swaab (1997) found a markedly decreased number of 
oxytocin neurons in the hypothalamic paraventricular nucleus. Hattori et al. 
(1985) reported a shortness of the frontal lobe, partial micropolygyria of the 
nucleus dentatus, heterotopia of the inferior olivary nucleus, ectopia of Purkinje 
cells in the molecular layer, heterotopia of the middle-sized neurons in the deep 
white matter of the cerebellum, and a large number of residual nerve cells in the 
cerebral subcortical white matter among the autopsy findings of a 23-year-old 
man who died due to acute renal failure. Reske-Nielsen and Lund (1992) 
described extensive calcifications of the central nervous system, mostly in the 
leptomeninges, the first and second layer of the cerebral and cerebellar cortex, 
and along the ventricular system in the autopsy of a 16-year-old boy who died 
from a cardiac arrest. An autopsy case by Hayashi et al. (1992) of a 6-month-
old girl with PWS and a deletion, who died from bronchopneumonia, showed 
disturbed undulating structures, resembling micropolygyria and pachygyria in 
the dentate nucleus and the inferior olivary nucleus, grumose degeneration of 
the nerve cells in the dentate nucleus, and heterotopia of the middle-sized 
neurons in the cerebellar white matter. Stevenson et al. (2004) reported on a 
deceased 9-month-old boy with PWS and deletion, whose brain autopsy 
revealed a mildly reduced neuronal population in the cerebral white matter, and 
concomitant neuronal heterotopia. Another child — a girl (PWS confirmed by 
methylation study, FISH negative) who died at the age of 3.5 years after an 
acute gastrointestinal illness, was reported to have had an abnormal gyrification, 
particularly of the occipital lobes, resembling polymicrogyria, an unusually 
deep third ventricle with a thin corpus callosum, and neuronal loss in the 
hippocampus (Stevenson et al., 2004). 
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2.5.2.4. Phenotype-genotype correlation 
 
All of the genetic mechanisms of PWS lead to a somewhat uniform clinical 
picture of neonatal hypotonia, with poor sucking and failure to thrive in the 
postnatal period, delayed psychomotor development, hyperphagia in early 
childhood resulting in obesity, short stature, hypogonadism, and peculiar 
behavioral problems (Table 3). Comparisons between the subgroups of PWS 
individuals indicate some subtle differences: 
i)  Hypopigmentation is the most distinctive feature in subjects with PWS and 
deletion. In addition, individuals with a larger type I deletion (BP1→BP3) 
tend to have a more severe phenotype than those with type II deletion 
(BP2→BP3), including greater self-harming behavior, deficits in adaptive 
behavior, obsessive compulsive behaviors, and difficulties with reading, 
mathematical skills, and visual-motor integration (Butler et al., 2004). 
Varela et al. (2005) pointed out that type I individuals acquired speech later 
than type II, and that seizures (especially febrile seizures) were six times 
more common in patients with PWS and deletion than in those with UPD. 
ii)  Subjects with UPD tend to have lower mean percentiles of birth weight and 
birth length compared to those with deletion (Gunay-Aygun et al., 1997a), 
and have a shorter course of gavage feeding and later onset of hyperphagia 
in females (Mitchell et al., 1996). They are less likely to have a typical 
facial appearance, and less frequently show some of the minor manifesta-
tions, such as skin picking, skill with jigsaw puzzles, a high pain threshold 
and articulation problems (Cassidy et al., 1997b). After adolescence, recur-
rent affective psychoses are relatively frequent in UPD individuals: these 
psychotic states have a subacute onset, polymorphous, shifting symptoma-
tology with an increase in psychomotor symptoms reminiscent of catatonia, 
and a need for psychiatric hospitalization with consecutive complete 
recovery (Vogels et al., 2004b; Verhoeven and Tuinier, 2006). 
iii) Little is known about the subjects with PWS and ID, but several case 
reports indicate that they display the typical PWS phenotype and age-
appropriate spectrum of symptoms, except hypopigmentation (Saitoh et al., 
1997; Ohta et al., 1999b; Buiting et al., 2000; Ming et al., 2000). They tend 
to have frequent respiratory problems and therefore increased risk of sudden 
infant death (Saitoh et al., 1997; Buiting et al., 2000; Ming et al., 2000); 
however, there may be an ascertainment bias because of the small number 
of described individuals with ID. 
 
 
2.5.2.5. Differential diagnosis 
 
The list of disorders that may present with neonatal/infantile hypotonia, 
developmental delay/mental retardation, obesity and hypogonadism is long, and 
 40
the diagnostic process is often very complex. Hypotonia in infancy is seen in 
the following conditions: hypoxic-ischemic encephalopathy, neonatal sepsis, 
metabolic encephalopathies, CNS congenital structural defects, and acquired 
hypothalamic insufficiency (Richer et al., 2001). A PWS-like phenotype has 
been described in patients with chromosome abnormalities involving the 
different chromosome regions: Xq23–25 duplication (Monaghan et al., 1998), 
1p36 deletion (D’Angelo et al., 2006), 4p deletion and duplication (Wieczorek 
et al., 2000; Richer et al., 2001), 6q deletion (Gilhuis et al., 2000; Varela et al., 
2006). Several disorders caused by single gene mutations can contribute to the 
floppy infant syndrome, such as spinal muscular atrophy (Richer et al., 2001), 
Albright hereditary osteodystrophy and Bardet-Biedl syndrome (Gunay-Aygun 
et al., 1997b), as well as Cohen syndrome (Kolehmainen et al., 2003), 
Börjeson-Forssman-Lehmann syndrome in males (Turner et al., 2004), fragile 
X syndrome (de Vries et al., 1993) and congenital myotonic dystrophy type I 
(Richer et al., 2001). 
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3. AIMS OF THE PRESENT STUDY 
 
The aims of the present study were: 
 
1.  To establish the birth prevalence and population prevalence of AS and PWS 
in Estonia. 
 
2.  To investigate the genetic etiology of patients with AS and PWS. 
 
3.  To ascertain the clinical symptoms facilitating early recognition of both 
syndromes. 
 
4.  To characterize the clinical phenotype of patients with AS and PWS. 
 
5.  To investigate the causes of early death in patients with AS and PWS. 
 11
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4. MATERIAL AND METHODS 
 
4.1. Study subjects 
 
The population-based epidemiological study was performed involving the 
whole of Estonia. From 2000 to 2004, we conducted a focused search for 
individuals with AS and PWS among children and adolescents aged 1 day to 18 
years born between 1984 and 2004. On the prevalence day, January 1, 2005, the 
total population of Estonia was 1,347,510 (620,600 males; 726,910 females), of 
whom 336,669 were 0–20 years old (172,496 males; 164,173 females) 
(Statistical Office of Estonia, final update on December 22, 2005). 
In the year before the onset of the study, the information about the study and 
detailed descriptions of AS and PWS were provided in the national pediatric 
meetings and in the continuous medical education courses at the Department of 
Pediatrics of the University of Tartu, Faculty of Medicine. According to a good 
medical practice guideline for Estonian family physicians, all children younger 
than 19 years of age with developmental problems should be referred to one of 
the two tertiary children’s hospitals for evaluation: in Tallinn for northern 
Estonia and in Tartu for southern Estonia. At the beginning of the study, 
introductory meetings were held at both hospitals. Study subjects were selected 
from the patients with developmental problems referred to these two hospitals. 
In addition, persons who had either been diagnosed with or were suspected to 
have AS or PWS in the past, but did not complete the diagnostic procedures, 
were invited for genetic re-evaluation, diagnostics and counseling. In order to 
find the undiagnosed individuals, in 2002 we visited all long-term-care and 
special educational facilities for disabled children in Estonia (28 sites with 1298 
residents). In all of the selected individuals we collected a brief case history, 
performed a clinical examination and took a blood sample (2–5 ml) for the 
DNA methylation test. All children with a positive DNA methylation test were 
subsequently seen at the Children’s Clinic of the University of Tartu. In all 
patients, a detailed medical and family history was collected using available 
medical documents and the questioning of parents or caregivers. Each patient 
with suspected AS underwent an awake and/or sleep EEG, and each patient 
with suspected PWS underwent electroneuromyography. In all cases an 
electrocardiogram (ECG), CT or MRI, X-ray for bone age evaluation, and 
abdominal ultrasonography were performed. All of these children were 
examined by a team consisting of a child neurologist, psychologist, 
physiotherapist, otorhinolaryngologist and an ophthalmologist. In addition, all 
parents of DNA methylation test positive but FISH negative patients gave a 
blood sample (5 ml) for further investigations. 
The total study sample included two subgroups: i) the retrospective group 
(born between 1984–1999) of subjects, who were selected using the consensus 
diagnostic criteria for AS (Williams et al., 1995) and PWS (Holm et al., 1993) 
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and ii) the prospective group (born between 2000–2004), which was selected 
using less stringent criteria in infants aged under 1 year; all infants with 
psychomotor developmental delay, marked congenital hypotonia or dystonia 
and seizure disorder of unknown cause were included. Children who were born 
in 2004 were followed up to the end of 2005. 
 
 
4.2. Methods 
 
In all selected persons with a clinical suspicion of AS or PWS, a blood sample 
(2–5 ml) was taken for the DNA methylation test. Patients with a positive test 
result were further investigated using cytogenetic and FISH analysis. Blood 
samples obtained from FISH negative patients and their parents were studied for 
UPD using polymorphic DNA markers. Blood samples of individuals with 
strong clinical evidence of AS but a negative methylation test were further 
investigated for mutations in the UBE3A gene. 
 
 
4.2.1. Methylation specific PCR 
 
DNA was extracted from whole blood with a genomic DNA purification kit 
(Gentra Systems, Minneapolis, USA), followed by sodium bisulfite treatment of 
the DNA (Kubota et al., 1997). The DNA was purified using the WizardR DNA 
clean-up system (Promega, Madison, USA). Methylation specific PCR of the 
SNRPN exon 1 region was carried out with primers SNRPN-common 5´-CTC 
CAA AAC AAA AAA CTT TAA AAC CCA AAT TCC-3´, SNRPN-Mat 5´-
TAT TGC GGT AAA TAA GTA CGT TTG CGC GGT C-3´, and SNRPN-Pat 
5´- GTG AGT TTG GTG TAG AGT GGA GTG GTT GTT G-3´ (Zeschnigk et 
al., 1997). PCR products (313 bp for maternal product, 221 bp for paternal 
product) were analyzed using electrophoresis, 2.5% agarose gel, and a tris-
borate buffer. 
 
 
4.2.2. Cytogenetic analysis and FISH 
 
Chromosomes were analyzed using peripheral blood and standard GTG banding 
(G bands by trypsin using Giemsa). Translocation of chromosomes 14 and 15 
was studied using FISH and probes CP5032 (D14Z1/D22Z1, chromosome 
14cen) (Oncor, Gaithersburg, MD), CEP 15 SG (D15Z1 classical satellite, 
chromosome 15p11.2), CEP 15 SO (D15Z alphoid DNA, chromosome 15cen), 
LSI SNRPN (SNRPN, chromosome 15q11.2-q12), and LSI PML (PML, 
chromosome 15q22) (Vysis Inc., Downers Grove, IL), BAC RP11–463i22 
(spanning from 25,725,185 to 25,892,792 Mb on chromosome 15q13.1, BAC 
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ends AZ515863 and AQ634845), and YAC 895h10 (D15S207, chromosome 
15q26). All other methylation test positive patients were studied using a DNA 
probe for the Prader-Willi/Angelman region (D15S63, SNRPN/imprinting 
center; chromosome 15q11-13) with a 15q telomere specific control probe 
(154P1) (Cytocell Ltd., Oxfordshire, UK). Usually 15 metaphases were 
analyzed per patient and per test. 
 
 
4.2.3. UPD analysis 
 
To trace the transmission of chromosome 15 from each parent to the child, the 
following set of microsatellites from outside the PWS/AS critical region was 
used: D15S123, D15S153, D15S125, D15S131, D15S100, and D15S211. PCR 
was performed using fluorescently labeled oligonucleotides and electrophoresis 
performed in an ABI 310 Genetic Sequencer (Applied Biosystems, Foster City, 
CA). 
 
 
4.2.4. UBE3A mutation analysis 
 
Ten protein encoding exons of the UBE3A gene (exons 7–16) were screened for 
sequence alterations, using PCR and conformation sensitive gel electrophoresis 
(CSGE) and direct sequencing. Primers for each exon were as described by 
Rapakko et al. (2004). CSGE was performed according to Körkkö et al. (1998). 
All of the band shifts detected by CSGE were further characterized by 
sequencing with the LI-COR IR4200 DNA Analysis System (LI-COR, Inc., 
Lincoln, NE). 
 
 
4.2.5. Statistical analysis 
 
Livebirth prevalence was estimated via the Generalized Linear Model Analysis 
using GENMOD procedure of the SAS system, Release 8.2 (SAS Institute, 
1999). The distribution of the prevalence cases was assumed to be binomial, and 
the default logit link function was used. The only variable factor in the model 
was the observation year. The mean (expected) prevalence rate for a given year 
and a corresponding 95% confidence interval were predicted with the OUTPUT 
statement of the GENMOD procedure. Differences were considered statistically 
significant if the p-value was less than 0.05. The study only included 
individuals with a genetically proven diagnosis of AS or PWS. 
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4.2.6. Ethical considerations 
 
The study was approved by the Ethics Committee on Human Research at the 
University of Tartu. Informed consent was obtained from the parents or legal 
guardians of the children, and none refused to participate in the study. 
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5. RESULTS AND DISCUSSION 
 
5.1. Birth prevalence and population prevalence of AS and 
PWS in Estonia (publication I) 
 
The study included a total of 188 persons: in the retrospective study group, four 
patients (2 with AS, 2 with PWS) had a genetically confirmed diagnosis, and 
over the period 2000–2004, 184 new index cases (93 with suspected AS, 91 
with suspected PWS) were identified and studied using MS-PCR. Twenty one 
of the index cases, 5 with suspected AS and 16 with suspected PWS, were 
included in the prospective study group, using the broadened selection criteria 
for infants less than 1 year old. In total, DNA MS-PCR test results were positive 
for 15 index cases, among them 7 infants from the prospective subgroup. 
Therefore the study comprised a total of 19 patients with a DNA proven 
diagnosis, seven of them had AS, and twelve PWS (Table 6). 
 
 
Table 6. Numbers of index cases and genetically confirmed cases 
 
 AS PWS 
Total number of subjects in this survey  95 93 
Number of index cases studied by MS-PCR (2000–2004) 93 91 
Number of index cases in retrospective subgroup 88 75 
Number of index cases in prospective subgroup 5 16 
Number of patients diagnosed in 1999 and earlier 2 2 
Number of MS-PCR positive cases in retrospective 
subgroup 
3 5 
Number of MS-PCR positive cases in prospective 
subgroup 
2 5 
Number of genetically confirmed study cases 7  
(4M/3F) 
12  
(4M/8F) 
 
Seven persons (two of them aged <1 year) had AS, and six of them (85.7%; two 
females, four males) showed a deletion of chromosome 15q11-13 (Table 7). 
The remaining female patient demonstrated paternal UPD (paternal age at birth 
was 30 years). Twelve persons had PWS (five of them aged <1 year), of whom 
four (33%; three females, one male) had 15q11-13 deletion and six (50%; four 
females, two males) had maternal UPD. Three out of the six mothers of children 
with PWS and UPD were older than 35 years (others were 24-, 32- and 33-year-
old). One child with PWS and UPD was conceived through assisted 
reproduction technologies (in vitro fertilization). Two persons with PWS had 
different chromosome rearrangements (Table 7). A boy with a positive 
methylation test showed a Robertsonian translocation of chromosomes 15q;15q, 
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but he moved abroad, and material for FISH and UPD studies was not available. 
One girl had an unbalanced translocation of chromosomes 14 and 15 resulting 
in a deletion of chromosome 15p13-q13. Using FISH, the deletion included the 
PWS critical region and BAC clone RP11–463i22, karyotype 
45,XX,der(14)t(14;15)(p11;q13).ish der(14)t(14;15)(D14Z1/D22Z1+,D15Z1–, 
SNRPN–,bac463i22/AQ634845–,PML+,yac895h10+). Clone RP11–463i22 
corresponds to the segment from 25,725 to 25,892 Mb on chromosome 15 
(UCSC Genome Browser, May 2004 assembly). The distal end of the typical 
15q11-13 deletions in the PWS and AS is defined by BAC RP11–48j4 
(http://www.sanger.ac.uk/PostGenomics/decipher), which spans from 24,346 to 
24,490 Mb on chromosome 15 (UCSC Genome Browser). Hence this girl had a 
deletion at least 1.4 Mb larger than typical 15q11-13 deletions. 
 
 
Table 7. Results of genetic studies 
 
Genetic diagnosis AS PWS 
15q11-13 deletion 6 5a 
Chromosomal translocation - 2b 
UPD15 1 6 
UBE3A mutation 1c - 
Total of genetically confirmed cases 7 12 
a  Including an unbalanced 14;15 translocation resulting in deletion of the PWSCR 
b Including the unbalanced 14;15 translocation and a Robertsonian translocation 
15q;15q 
c  Familial polymorphism, most likely not the causal mutation 
 
 
UBE3A mutation screening was performed in six individuals with a normal 
methylation test result, who were selected based on a strong clinical suspicion 
of AS (Moncla et al., 1999a) (Table 8). One person showed an aberrant 
fragment by CSGE in a large exon 9 of the UBE3A gene, and a missense 
mutation of codon 243 (nt1315C>A, Asn243Lys) was detected through 
sequencing. However, the father of the patient had the same sequence variation, 
supporting the phenotypically silent nature of this polymorphism. 
 From 1984 to 2004, the annual number of births in Estonia decreased from 
24,234 (peak in 1987–1988 with 25,086 and 25,060 births, respectively) to 
13,992 newborns (Statistical Office of Estonia, www.stat.ee) (Figure 1). 
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Table 8. Clinical findings of patients investigated for UBE3A mutations 
 
Clinical finding KH JK JuK BP KMS RT 
Severe developmental 
delay + + + + + + 
Speech impairment + + + + + + 
Movement/balance 
disorder + + + + + + 
Relevant behavior + + + + + + 
Microcephaly +  + + + + 
Seizures + + + + +  
Flat occiput  + + + +  
Protruding tongue  +  + +  
Prognathia  + + + +  
Wide mouth, widespaced 
teeth + + + + +  
Strabismus + + + + +  
Sleep disturbance  + + + +  
Fascination with water   + +   
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Figure 1. Numbers of live births, AS and PWS cases in Estonia from 1984 to 2004 
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A total of 365,266 live births were recorded, indicating a minimum livebirth 
prevalence of 1:52,181 (95% CI 1:25,326–1:129,785) for AS and 1:30,439 
(95% CI 1:17,425–1:58,908) for PWS. On the prevalence day, January 1, 2005, 
the total number of persons aged 20 years and under was 336,669. Among AS 
and PWS persons, a girl with AS and a deletion and a girl with PWS and the 
deletion died before the prevalence day. Thus, among children and adolescents 
in Estonia, the prevalence of AS (six prevalent cases) was 1:56,112 (95% CI 
1:1:25,780–1:152,899), and the prevalence of PWS (11 prevalent cases) was 
1:30,606 (95% CI 1:17,105–1:61,311). 
 Statistical analysis showed an increase in the livebirth prevalence of AS 
during the years 1984–2004, from 0.88 cases per 100,000 livebirths or 
1:113,636 (95% CI 1:23,923–1:526,316) to 4.23 cases or 1:23,640 (95% CI 
1:6,658–1:84,034). However, this trend was not statistically significant (p=0.2) 
(Figure 2). For PWS we noticed a more substantial, statistically significant 
increase (p=0.032) in the livebirth prevalence, from 1.13 cases per 100,000 
livebirths or 1:88,495 (95% CI 1:24,390–1:320,580) to 7.97 cases or 1:12,574 
(95% CI 1:540 — 1:29,154) (Figure 3). 
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Figure 2. Distribution of AS birth prevalence in Estonia from 1984 to 2004 by 
statistical logit analysis. The dashed lines indicate the 95% confidence interval. 
 
 
 13
 50
 1984                   1988                   1992                    1996                   2000                   2004
Year
PW
S 
bi
rth
 p
re
va
le
nc
e  
(c
a s
e s
 li
v e
b i
rth
-5
) 14
12
10
8
6
4
2
0
 
 
Figure 3. Distribution of PWS birth prevalence in Estonia from 1984 to 2004 by 
statistical logit analysis. The dashed lines indicate 95% confidence interval. 
 
 
To our knowledge, this is the first epidemiological study to estimate the birth 
prevalence and population prevalence of genetically proven AS and PWS in the 
same population at the same time. The birth prevalence and population 
prevalence data presented by us for AS and PWS from 1984–2004 are 
somewhat lower than those previously reported (Table 4), where the 
calculations were based on selected populations, short study period or, in earlier 
studies, used patients without a genetically confirmed diagnosis. 
The first population-based study by Clayton-Smith (1993a) estimated the 
minimum population prevalence in the UK at 1:62,000, considering clinically 
and genetically confirmed AS individuals, mainly among referrals to genetic 
consultation. Other previous studies on AS ascertained patients based on their 
disabilities (mental retardation, epilepsy) (Kyllerman, 1995; Jacobsen et al., 
1998; Vercesi et al., 1999), used a shorter study period (Kyllerman, 1995; 
Petersen et al., 1995), and/or included ≥50% persons without a genetically 
confirmed diagnosis (Kyllerman, 1995; Buckley et al., 1998; Thomson et al., 
2006). Our data for AS showing a 1:52,181 prevalence in liveborns and a 
1:56,112 population prevalence in persons under 20 years of age are based on a 
relatively large and well-defined data set and may be the most reliable. 
However, the expected birth prevalence at the end of this study period was 
1:23,640 (2 times higher, p=0.2). Over the period 2001–2004 when the 
broadened inclusion criteria were used, the actual live birth prevalence was 
1:26,331, indicating that the expected and achieved results did not differ 
significantly, and we probably did not miss any AS cases. The increased 
incidence could possibly be explained by either a true incidence increase in the 
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syndrome, improved diagnostic possibilities, or a focused search for the 
syndrome. 
We included in our AS group only persons with a confirmed genetic 
diagnosis, considering the variety of mimicking conditions and the debate over 
yet undetermined mechanisms causing AS in 10–15% of “clinically definite” 
cases (Rougeulle et al., 1998; Herzing et al., 2001; Lossie et al., 2001; Landers 
et al., 2005). A phenotypic overlap has been reported between AS and MECP2 
mutations, and MECP2 mutation screening has been proposed for AS patients 
without a demonstrable genetic lesion of chromosome 15q11-13 (Watson et al., 
2001). We collaborated in a study ascertaining the incidence of MECP2 
mutations among patients with an Angelman-like phenotype but no detectable 
lesion of chromosome 15. However, none of these persons, five boys and four 
girls, showed a relevant MECP2 mutation (Ylisaukko-Oja et al., 2005). 
Our data for PWS indicate a mean livebirth prevalence of 1:30,439. To date, 
there have been two previous DNA methylation test-based studies providing 
similar data on incidence at birth, 1:25,000 from Australia for a three year 
period (Smith et al., 2003a), and 1:26,676 from Flanders, Belgium, considering 
eight consecutive years (Vogels et al., 2004a). In our 21-year-study (1984–
2004), the mean livebirth prevalence of 1:30,439 is lower, but not significantly, 
which may be explained by the considerably longer study period. Nevertheless, 
the statistically expected prevalence of 1:12,547 (2.4 times higher and 
statistically significant (p=0.032) increase) and the observed livebirth 
prevalence of 1:10,532 at the end of the study period and during the years 
2001–2004 are comparable, indicating that we probably did not miss any cases 
of PWS. These results could indicate a true increase in PWS prevalence or, 
alternatively, may be explained by early testing and an improvement in neonatal 
care. The age of women giving birth has increased over the study period from 
25.9 in 1984 to 27.9 years in 2004, although the proportion of those older than 
30 years of age has remained the same. Therefore, a change in maternal age did 
not seem to be of significance for the increased occurrence of PWS in Estonia in 
recent years. 
It is important to emphasize that our findings contradict the widespread 
opinion that AS and PWS are equally frequent. The livebirth prevalence and 
population prevalence of AS was lower than that of PWS by a factor of 1.7 and 
1.8, respectively. We observed some periodic fluctuations in the birthrates of 
both syndromes (Figure 1). There were several years with frequent or infrequent 
AS and PWS cases that could easily influence the prevalence data over short 
periods of time. We assume that we missed no AS and PWS patients during the 
last 4 year period (2001–2004). There is, however, a possibility that we lost 
patients before the study period due to death. Different medical complications 
may develop in individuals with AS or PWS (Clayton-Smith, 2001; Butler et 
al., 2002), and during our study a 3.5-year-old girl with AS died of Reye 
syndrome. However, early death appears to be more common in PWS (Hayashi 
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et al., 1992; Clericuzio et al., 1997; Schrander-Stumpel et al., 1998; Schrander-
Stumpel et al., 2004; Stevenson et al., 2004; Nagai et al., 2005). Even with an 
added 10–15% “clinically definite”, but not genetically confirmed cases of AS 
(10%=0.7 patient or maximum 1 patient in our study), the livebirth prevalence 
of AS remains 1.5 times lower than that of PWS. 
We identified no cases of UBE3A gene mutations causative for AS or 
imprinting mutations. These mutation types are rare. Imprinting mutations are 
primarily detected by the DNA methylation test and as the core clinical features 
are not different, we probably missed none of these patients (Buiting et al., 
1995; Saitoh et al., 1997; Buiting et al., 1999; Gillessen-Kaesbach et al., 1999; 
Ohta et al., 1999a; Ohta et al., 1999b; Buiting et al., 2001; Buiting et al., 2003). 
On the other hand, the 50% rate of UPD among individuals with PWS was 
surprisingly high, and three (50%) of these six mothers were older than 35 
years. Recently, Whittington et al. (2006) reported a greater proportion (50%) 
of UPD in children with PWS under 5 years of age living in the UK. They 
explained the changed rates of genetic subtypes by increasing maternal age at 
conception in this generation of mothers, but they did not provide data 
concerning increased/changed prevalence of PWS. In Estonia from 1984 to 
2004, the proportion of women giving birth when older than 30 years of age has 
remained the same, and the subjects with UPD were evenly distributed during 
these years. Therefore we cannot associate the markedly different proportions in 
genetic mechanisms of PWS with recently increased maternal age at 
conception. One child with PWS and UPD was born after in vitro fertilization 
(IVF), although at present IVF is thought to be a causative for epigenetic 
modifications which may play an important role in the increased rate of 
imprinted gene abnormalities (Lidegaard et al., 2005; Allen et al., 2006). 
Nevertheless, the role of assisted reproductive technologies in adverse outcomes 
needs further clarification and population-based comparative studies will be 
needed before definitive conclusions can be drawn. Furthermore, we identified 
two new cases of PWS caused by chromosomal translocations, which is usually 
a very rare cause of PWS (<1%). All these differences might just be 
coincidental, as our group of patients was small, but taken together they provide 
some additional argument that we most likely missed very few if any PWS or 
AS cases. 
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5.2. Clinical phenotype of AS and PWS patients  
(publications II, III, IV) 
 
5.2.1. Clinical phenotype of AS 
 
5.2.1.1. Phenotype of patients with AS 
 
In total, seven children (3 girls, 4 boys) born between 1984 and 2004 were 
diagnosed with AS. During the study period (2000–2004) we identified five 
patients, two girls and three boys. The overall diagnostic frequency was 5.4% (5 
cases in 93 suspected patients), although considering the patients born from 
2000–2004 (prospective subgroup), the diagnostic frequency was 40% (2 cases 
in 5 suspected patients). This difference partly shows the importance of clinical 
experience — all 88 patients born between 1984 and 1999, who were studied 
using MS-PCR for AS (the diagnostic test available in Estonia since 1998), 
showed marked developmental delay with speech impairment, movement or 
balance disorder, and behavioral disturbances characteristic of AS. The 
experience gained greatly facilitated the much earlier recognition of the two 
most recent patients (the clinical suspicion arose during the first year of life and 
confirmed diagnosis was made at 13 and 14 months respectively). The mean 
age of diagnosis considering all seven patients was 6.1 years. Recent studies on 
a series of patients with AS have reported the mean age at diagnosis of 10.2 y 
(Laan et al., 1997), 7y 7m (Molfetta et al., 2003), and 5y 8m in patients with 
deletion and 9y in those with UPD (Varela et al., 2004b). These data show that 
AS is being recognized at an earlier age. 
All subjects with AS in our study were born at term with normal (< +/- 1SD) 
birth weights (3100–3994 g), lengths (49–52 cm), and Apgar scores (available 
for five subjects; > 7 in the first minute of life). Head circumference (HC) 
measurements at birth were available in the case of three subjects — two were 
between mean and +1 SD, and one subject (UPD) showed HC <50th percentile. 
There was normal prenatal and birth history for four subjects, and three subjects 
(43%) were born after a complicated pregnancy: one was in a forehead position, 
one was born from a pregnancy with abnormal double-test result (amniocentesis 
showed normal karyotype 46,XX), and one pregnancy was with twins, where 
the second fetus died at 5–6 weeks of pregnancy. All newborns were discharged 
from the maternity hospital as usual, and none of them was hospitalized during 
the first six months of life. During the first months of life, however, one child 
had feeding difficulties with frequent regurgitation of feeds, and three children 
were irritable and had sleep disturbance. When the children reached the age of 
six months, all mothers and also family physicians began to seek consultation 
with a child neurologist due to developmental problems and deceleration in 
head growth. The problems noticed by neurologist were truncal hypotonia, 
dystonia, and spasticity of the lower limbs. All children were passive but smiled 
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frequently; tongue thrusting was noticed in only one subject. In those with HC  
-2 SD (three subjects), the head growth retardation began after five months of 
age and reached the point of -2 SD at 10 months of age in one subject and at the 
age of 2 years in the other subject. The corresponding data were not available 
for the third subject. 
The number of patients with AS was small (Table 9), and only two subjects 
were younger than 1 year old when the suspicion of AS arouse, and therefore it 
is difficult to determine the seminal symptoms that may facilitate early 
diagnosis. In spite of the generally supported observations that normal prenatal 
and birth history are typical of children with AS (Fryburg et al., 1991; Clayton-
Smith, 1993c; Williams et al., 1995; Smith et al., 1996; Williams et al., 2006), 
we found various complications during pregnancy and birth in three out of 
seven (43%) children. However, they all showed normal growth parameters at 
birth. A recent update of the diagnostic criteria and some previous reports have 
pointed out frequent feeding difficulties at neonatal and infantile age (Van 
Lierde et al., 1990; Clayton-Smith, 1993c; Smith et al., 1996; Williams et al., 
2006), but only one child in our study group had problems with feeding. Three 
out of seven (43%) in our study group were irritable and had decreased sleep 
during the first six months of life, features that are rarely described within early 
infantile development (Schulze et al., 2001). Nevertheless, it is remarkable that 
the parents and family physicians of all of our patients with AS were seeking 
specialized neurological consultation even before the children were six months 
old. In all children the neurologist noticed delayed motor development, truncal 
hypotonia, and brisk deep tendon reflexes in association with small HC. It has 
been noticed by previous investigators (Fryburg et al., 1991; Smith et al., 1996) 
that the growth of HC tends to stagnate, and children with AS and deletion 
appear to be remarkably microcephalic by two years of age. Two of our patients 
had normal HC (one with UPD), two had HC that deviated by -1 SD, and three 
(43%) were markedly microcephalic by the age of two years. Even if the 
stagnation of head growth cannot serve as a universal symptom, it is alarming, 
especially in conjunction with marked developmental delay. Excessive tongue 
thrusting and drooling with a mainly happy disposition has previously been 
described in babies with AS (Van Lierde et al., 1990; Yamada and Volpe, 1990; 
Fryburg et al., 1991; Clayton-Smith, 1993c; Bottani et al., 1994; Schulze at al., 
2001). Only one child in our study group was noticed to have remarkable 
tongue thrusting at the age of eight months, while all others were described as 
passive with an apparent happy demeanor. The most constant finding within the 
first neurological examination was marked truncal hypotonia, which was 
noticed in six children. Considering previous observations (Fryburg et al., 1991; 
Clayton-Smith, 1993c; Smith et al., 1996), updated consensus concerning 
diagnostic criteria (Williams et al., 2006) and our own experience, the global 
developmental delay with overt truncal hypotonia, in association with happy 
demeanor and/or disproportionate growth in HC, could serve as the guiding 
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symptom complex for early diagnosis of AS. Our experience with children 
under 1 year of age proved: (i) the usefulness of broadened selection criteria 
(psychomotor developmental delay, marked congenital hypotonia or dystonia, 
and seizure disorder of unknown origin) — early diagnosis of AS considerably 
diminished pressure on medical staff and facilitated appropriate management; 
(ii) our family physicians are well-trained to recognize developmental problems 
and seek consultation from a child neurologist at an early stage; (iii) the parents 
had marked difficulty accepting the diagnosis of AS in early age, showing 
hopelessness and denial. 
Four patients (57%) with AS had epilepsy. Two patients (NL, MM) 
demonstrated infantile spasms at 6 and 10 months of age respectively, which 
gave the indication for the first EEG. In both cases the EEG revealed a 
hypsarrhytmia-like pattern — irregular generalized high-voltage slow activity 
with multifocal spikes and sharp waves. Antiepileptic treatment with valproic 
acid was successful in both patients. One patient (MV) had two consequent 
febrile seizures at the age of 2 years, after that epilepsy with myoclonic 
absances was diagnosed, and subsequent treatment with valproic acid was 
effective. He demonstrated an EEG pattern typical of young children with 
AS — runs of high amplitude (>200µV) 3–4/s rhythmic activity, maximal over 
the occipital region and containing spike waves. The EEG findings facilitated 
the diagnosis of AS, which was made at the age of 2y 7m. The fourth subject 
(HE) was 1y 8m old when generalized tonic-clonic seizures began. In his case 
the treatment with carbamazepine and valproic acid was ineffective, 
clonazepam worked well, but he still has 1 or 2 short partial seizure attacks per 
year. His EEG at the age of 11y3m showed persistent rhythmic 5 Hz theta 
activity intermittently with high-voltage spike and slow wave complexes over 
the frontoparietal regions, with bursts of generalized slow high-voltage delta 
activity. For three patients without epilepsy (1y 1m; 8y; 13y), EEG showed a 
slow and disorganized background rhythm. 
Specific EEG findings and the early onset of epilepsy facilitated the 
diagnosis of AS in three patients (MV, MM, NL). The fourth patient (HE) was 
strongly suspected of having a metabolic disorder and the diagnosis of AS was 
made at the age of 10y 7m, when he demonstrated the entire phenotype of AS. 
The EEG abnormalities found in patients with AS are not pathognomonic to AS 
and have to be seen in the appropriate clinical context (Laan and Vein, 2005). 
Moreover, the changes in EEG alter with age, being more prominent in younger 
patients and less apparent after the age of 10–12 years (Boyd et al., 1988; 
Matsumoto et al., 1992; Clayton-Smith, 1993c; Casara et al., 1995; Laan et al., 
1997; Buoni et al., 1999). 
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Despite the fact that EEG abnormalities are usually manifested in the first 2 
years of life, the abnormal EEG indicating possible AS is uncommon before the 
age of six months (Boyd et al., 1988; Casara et al., 1995). Therefore the EEG as 
a tool for early recognition of AS is not very helpful within the first half-year of 
life (when all of our patients were consulted by child neurologists), and several 
EEG recordings are often needed to find the typical pattern (Laan and Vein, 
2005). The early onset of seizures and repeated EEGs have facilitated the 
diagnosis of AS in our patients. Surprisingly, none of the patients with AS in 
our study group showed severe epilepsy that was difficult to control as it has 
been described in the literature (Viani et al., 1995; Guerrini et al., 1996; Laan et 
al., 1997; Valente et al., 2005). All our patients with epilepsy received 
monotherapy: one with clonazepam and two with valproic acid. The early 
recognition of seizure disorder and careful AED adjustment with concomitant 
monitoring of serum concentration of AED may have played a role in adequate 
seizure control in the children in our study. The 57% rate of epilepsy (4 patients 
out of 7) in our AS group was lower than the previously reported 80% 
(Matsumoto et al., 1992; Williams et al., 1995; Laan et al., 1997; Buoni et al., 
1999; Williams et al., 2006). 
Three patients (43%) were suspected of having metabolic disturbances 
before the diagnosis of AS was made: two of them (MM, RS) demonstrated 
generalized organic aciduria (MM was treated with vitamins B1 and B6, and 
biotin), and one (HE) had primary lactic acidosis and was also treated with 
vitamins. In general, children with AS lack any significant biochemical/ 
metabolic abnormalities (Williams et al., 1995; Williams et al., 2001; Williams 
et al., 2006). Nevertheless, Williams et al. (2001) have described two children 
with mild lactic acidosis and encephalomyopathy who subsequently had 
resolution of their lactic acidemia and had positive genetic testing for AS. 
 MRI/CT showed a various degree of brain atrophy in four patients (57%): 
mild ventriculomegaly in three patients, with concurrent mild cortical atrophy in 
two cases, and an asymmetrical enlargement of the lateral ventricles in one 
patient. The neuroradiological findings of our patients were nonspecific and 
similar to those described in the literature: symmetrical or asymmetrical 
enlargement of the lateral ventricles, mild cortical atrophy, and dysmyelination 
in approximately 50% of patients with AS (Casara et al., 1995; Guerrini et al., 
1996; Buoni et al., 1999). We were unable to identify any structural anomaly 
that originated from the early stage of brain development in our patients with 
AS. This concurs with the prevailing view that the CNS defects responsible for 
cognitive deficits and balance and/or movement disorder in AS may be too 
subtle to affect gross brain morphology (Leonard et al., 1993; Williams et al., 
1995; Williams et al., 2006) or evolve in the course of time, and therefore 
further investigations are needed in order to acquire a better understanding of 
the pathological mechanisms of AS. 
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Interestingly, all children with the deletion of 15q11-13 who were older than 
2 years developed the bottom-shuffling, quite unusual form of motion among 
children with other causes of mental retardation. The reason for this behavior 
could be a compensation for truncal ataxia and hypotonia. Moreover, one 
patient demonstrated severe generalized resting tremulousness (KK), a poorly 
understood and not universal clinical manifestation of AS. Another patient (NL) 
was 6 months old when a marked tremor in the upper extremities was noticed, 
and the third patient (MM) developed athetotic involuntary movements, which 
mostly involved the lower extremities. It has been shown that one third of older 
AS individuals suffer from worsened tremor compromising their ability to be 
ambulant and to feed themselves (Clayton-Smith, 2001). Moreover, two adults 
with a deletion (Harbord, 2001) and one with an UPD (Jacobsen et al., 1998) 
were described as presenting typical Parkinson disease, and the deletion patients 
demonstrated a good response to levodopa medication. Long-term observations 
are needed to clarify the connection between childhood movements/balance 
disorders and the development of Parkinsonism in older age. 
In conclusion, according to our study and considering the data from the 
literature (Van Lierde et al., 1990; Yamada and Volpe, 1990; Fryburg et al., 
1991; Clayton-Smith, 1993c; Williams et al., 1995; Smith et al., 1996; Schulze 
et al., 2001; Williams et al., 2006), testing for AS in the first year of life is 
indicated when a combination of the following symptoms are present: 
irritability, sleep disturbance, feeding difficulties, developmental delay with 
slow progression of head growth, truncal hypotonia with pyramidal signs, 
specific EEG pattern and/or seizures. 
 
 
5.2.1.2. Bone abnormalities and AS (publication II) 
 
Bone age was available for five patients, and this corresponded to chronological 
age in only one patient. Two patients had an accelerated bone age: MM at the 
age of 3y 2m demonstrated a bone age of 3y 9m and RS at the age of 1y 1m had 
a bone age of 1y 6m according to Tanner-Whitehouse radius, ulna, and short 
bones score (TW-RUS). Two patients showed delayed bone age: HE had a bone 
age corresponding to the age of 10 years when he was 11 years old and KK 
showed a bone age of 8.1 years when she was 13 years old. KK also 
demonstrated unusual marked limb deformities, generalized osteoporosis, and 
brachydactyly type B. 
Case report of KK. She was born at term after an uneventful pregnancy and 
delivery with normal birth weight, length, HC and Apgar scores. During the 
first months of life she was irritable and had difficulty sleeping. She started to 
sit at 9 months, pulled herself to a standing position at 13 months, but she never 
began to walk independently. The patient was evaluated at the age of 21 months 
at Tartu Children’s Hospital due to developmental delay and lack of speech. She 
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underwent full clinical investigation without significantly abnormal results, only 
her bone age was 7 months behind the chronological age. Her karyotype was 
normal (46,XX). The cause of her developmental delay at that time remained 
unclear. She was next hospitalized at the age of 13.3 years due to a marked 
developmental delay and severe limb deformities. On examination, her weight 
was 22 kg (-3 SD) and HC 51.5 cm (-2 SD). Her height was not measurable due 
to severe limb deformities. There was a pigmented spongy formation with a 
diameter of 3 cm on her forehead. She still had milk teeth. There was no breast 
development and she had few pubic hairs. Her fingers were short and wide, 
especially the thumb and first toe. She had a marked generalized resting tremor, 
an intentional tremor and truncal ataxia, and she moved by bottom-shuffling or 
on her hands and knees. Her tendon reflexes were slightly exaggerated with no 
pathological reflexes, and her muscle tone was considered normal. 
X-ray investigations demonstrated generalized osteoporosis. The femur, 
tibia, fibula, ulna and radius showed curved deformities in the distal diaphysis-
metaphysis areas. The compact layer possessed marked changes of rebuilding, 
the epiphyses were dysmorphic, and the epiphyseal lines were porous. Her bone 
age was 8.1 years according to TW-RUS. The distal phalanges of all her fingers 
were short. The left hand lacked the epiphyses of the distal phalanges of the II, 
III and V fingers, and the right hand lacked the epiphyses of the distal phalanges 
of the III and V fingers. On both hands the III metacarpal bone was 
hypertrophic with a curve to the palmar side. The biochemical results were as 
follows: normal ionized calcium 1.18 mmol/l (normal range 1.17–1.29), mildly 
decreased phosphorus 1.01 mmol/l (normal range 1.1–2.0) and slightly elevated 
parathyroid hormone 8.72 pmol/l (normal range 1.5–8.1). Alkaline phosphatase 
(ALP) was elevated 1179.0 U/L (normal range 70–300). Markers of bone 
formation (bone ALP iso-enzymes 888.3 U/L (normal range < 140) and 
osteocalcin 149.8 ng/ml (normal range 11–43)) and markers of bone resorption 
(desoxypyridinolin creatinin ratio 40 nmol/mmol (normal range 4.2–35.7) and 
C-telopeptide 1.93 ng/mmol (normal range 0,025–0,573)) were all elevated, 
indicating rapid bone turnover. The serum 25-hydroxyvitamin D3 level of 2.4 
µg/l (normal range 9.0–37.6) was significantly reduced. The excretion of 
phosphorus and calcium in urine were within normal limits. The serum 
quantitative amino acids analysis was normal, and there was generalized 
hyperaminoaciduria in the urine. The syphilis RPR latex test was negative. 
To our knowledge the association of AS and marked limb deformities as 
well as brachydactyly has not previously been reported. The scabbard-like 
lower limb deformities in our patient resembled the changes associated with 
congenital syphilis, but the syphilis RPR latex test was negative. The 
generalized osteoporosis can be explained by the patient’s severe disability, 
delayed puberty and presumable nutritional and environmental deficits 
(vitamin-D-deficient rickets). Considering that patients with AS have problems 
with bone maturation, delayed dentition, microcephaly, scoliosis and kyphosis, 
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it is possible that gene(s) causing AS play a role not only in the development 
and maturation of the brain, but also in the process of bone formation. 
The clinical manifestations of scoliosis and/or kyphosis are consistently 
described in the independent series of AS patients and appear to become more 
pronounced or visible with advancing age (Buntinx et al., 1995; Sandanam et 
al., 1997; Clayton-Smith, 2001). These features could be nonspecific and are 
relatively common in adults with other severe developmental disabilities, 
related mostly to decreased mobility and wheelchair dependence. However, the 
fact that these features were present in several independent series of AS patients 
in different age groups indicates the possibility that scoliosis and/or kyphosis 
are clinical features of AS that are probably explainable by genetic factors. 
The shortening of the distal phalanges of all of the fingers and the absence of 
some epiphyses of the distal phalanges in our patient can be classified as 
brachydactyly type B, typically characterized by the absent or hypoplastic 
terminal portions of digits II–V of the hands and/or feet (Winter et al., 1993). 
Brachydactyly may be either sporadic, part of an isolated familial brachydactyly 
or a feature of various skeletal dysplasias or syndromes: at least 345 syndromes 
and skeletal dysplasias with brachydactyly have been described, including PWS 
(Winter, 2001). Our patient had hypertrophic curved III metacarpal bones, 
probably caused by asymmetric shortening of other metacarpal bones typical to 
brachydactyly type B. Small hands and feet are often cited as a manifestation of 
PWS, but the shortening of hands and feet have not been specified (Hudgins 
and Cassidy, 1991). In AS, brachydactyly or shortening of the hands and feet 
have not to our knowledge been described before. The brachydactyly in our 
patient is probably a sporadic finding, although as our group of patients with AS 
was small, we cannot rule out the possibility that this feature is more frequent in 
AS. 
Absolute or relative microcephaly is another frequent symptom of AS 
(Fryfurg et al., 1991; Buntinx et al., 1995; Williams et al., 1995; Smith et al., 
1996). Head circumference is usually normal at birth, but head growth 
decelerates during the early years of life (the first year), and many individuals 
with AS become microcephalic. Two of our patients had normal HC (one with 
UPD), two had HC measurements that deviated by -1 SD, and three were 
markedly microcephalic by the age of two years. In addition, several typical AS 
features such as mid-face hypoplasia, prognathism and delayed and disturbed 
dentition had been explained by brain development abnormality or behavioral 
phenotype (Clayton-Smith, 1993c), although these features could just as likely 
be consequences of abnormal bone maturation, as four children (57%) in our 
study group demonstrated abnormalities in bone growth. 
The UBE3A gene, which is known to play an important role in the 
development of the characteristic clinical phenotype of AS (Kishino et al., 
1997; Matsuura et al., 1997; Sutcliffe et al., 1997), encodes the protein with two 
separable independent functions — a ligase and a coactivator for the nuclear 
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hormone receptor superfamily (Nawaz et al., 1999). Coactivators with 
additional enzymatic activity are thought to play an important role in regulating 
the magnitude of the biological response to steroids, vitamin D and retinoids in 
different tissues. Nawaz et al. (1999) found that in the majority of the examined 
patients with AS, the UBE3A ligase function was defective, but the coactivator 
function was intact. It is, however, possible that deletions of UBE3A can result 
in defective steroid receptor coactivation in tissues where UBE3A is expressed 
in an imprinted manner. To our knowledge, there are no available data of 
UBE3A expression in bone tissue. It is likely that the defective function of 
UBE3A influences organ growth, including bone formation and mineralization, 
or the severity of the manifestation of rickets. 
Patients with PWS frequently develop osteoporosis and scoliosis at any age 
and kyphosis mostly in early adulthood (Cassidy et al., 2000). Osteoporosis in 
PWS is thought to originate from the combination of decreased production of 
sex or growth hormones and/or long-standing hypotonia. Interestingly, in PWS 
both bone mineral content and bone mineral density tend to be reduced, 
especially in the limbs (Brambilla et al., 1997; van Mil et al., 2001). It is 
plausible that in AS and PWS a certain gene or genes are responsible for bone 
formation and/or mineralization, as our patient KK’s deformities and severe 
osteoporosis mostly involved the extremities, and the proportion of children 
with deviated bone age was almost the same (57% AS, 67% PWS) in both 
group of patients. 
 
 
5.2.2. Sudden death and autopsy in the case of AS 
 
Interestingly, three patients (43%) in our series of AS children were at first 
suspected of having metabolic disturbances: two of them (MM, RS) 
demonstrated generalized organic aciduria and one patient (HE) was diagnosed 
with primary lactic acidosis. Unfortunately, patient MM died of cardiac arrest 
one months and three weeks after falling into a coma due to putative Reye-like 
syndrome. 
Case report of MM. MM (Table 9) was born after an uncomplicated full 
term pregnancy as the fourth child in the family (birth weight 3120 g, length 47 
cm, HC 36 cm, Apgar score 8/8). On the 16th week of pregnancy an 
amniocentesis was performed due to advanced maternal age (37y), which 
revealed normal fetal karyotype (46,XX). However, since the first month of her 
life the mother was worried because of her extremely slow psychomotor 
development. At the age of nine months MM was referred to Tallinn’s Children 
Hospital due to marked developmental delay. At that time her HC was 43.5 cm 
(-1 SD), she could not sit, crawl or stand, and her muscle tone was dystonic 
with marked truncal ataxia. Brain US showed slight ventriculomegaly 
(sin>dex), amino acid analysis of the serum revealed slightly elevated cysteine, 
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and alkaline phospatase (ALP) was 488 U/L (normal range <462 U/L). She was 
re-admitted and thoroughly investigated at the age of 16 months. The mother 
complained about the jerks that had been present during the last 5–6 months and 
a periodic appearance of tonic posture. On examination, she was very pale with 
a slight rash of diathesis on her cheeks. Her tongue was relatively large. Her 
muscle tone was hypotonic, with slight spasticity in the lower extremities, and 
bilaterally spontaneous Babinski reflex. HC was 45 cm (-1 SD), and she had no 
speech. She was able to sit when seated, and crawl. Her ENMG was normal, but 
her EEG showed hypsarrhythmia. Laboratory findings showed metabolic 
acidosis (ABE –7.5 mmol/l), but the anion gap was normal (19.0 mmol/l). 
Amino acid analysis of the serum and urine was normal; lactate was 2.0 mmol/l. 
Ammonia in plasma was initially mildly elevated — 85 µmol/l (normal range 
<50 µmol/l), but when repeated one month later it was normal. Urinary organic 
acid gas-chromatography/mass-spectrometry (GC/MS) showed mildly increased 
excretion of adipic acid (82 mmol/mol crea, normal <34.3), sebacic acid  
(2.1 mmol/mol crea, normal <1.4), 3-OH-isobutyric acid and 3-OH-isovaleric 
acid. The acyl-carnitine profile was normal by tandem mass-spectrometry, 
which excluded fatty acid oxidation defects in this patient. The origin of her 
developmental delay remained unclear, but epilepsy was suspected and 
treatment with valproic acid and vitamins B1, B6 and biotin was begun. Later 
she was repeatedly seen by a pediatric neurologist. Her ammonia was elevated 
(120 µmol/l) again after 5 months of valproic acid treatment, and metabolic 
acidosis persisted. The level of ammonia remained elevated — 90 µmol/l,  
52 µmol/l, 73 µmol/l (ALP 621 U/L, normal range <462 U/L). A brain CT was 
performed at the age of 23 months and showed mild ventriculomegaly and mild 
frontal atrophy. When 2y 5m old, she had normal growth, with height  
90 cm (0 SD), weight 15.5 kg (0 SD), but microcephaly (HC 46 cm, –2 SD). 
She was severely mentally retarded with a hypomimic face, fair hair, a small 
and upturned nose, everted lower lip, mild prognathia, autistic behavior, 
frequent smiling and absent speech. There were marked axial hypotonia and 
truncal ataxia, slight spasticity in her lower limbs, exaggerated deep tendon 
reflexes with pathological reflexes (Babinski), and episodic athetotic 
movements. She could walk only with support. AS was clinically suspected and 
confirmed by a positive DNA methylation test, which revealed that the maternal 
allele was missing in AS/PWSCR. Later on, FISH analysis showed micro-
deletion in region 15q11-13. At the age of 3y 3m the brain MRI did not show 
any focal abnormalities in her brain tissue. 
At the age of 3y 5m she was hospitalized to the intensive care unit due to 
persisting high fever in the past three days, recurrent tonic seizures and 
presumed unconsciousness. Acetaminophen was repeatedly administered at 
home, but to no avail. She was immediately intubated, and assisted ventilation 
was begun. She had mild hepatomegaly and a maculose skin rash around her 
mouth, which was suspected to be a herpes virus (HV) infection, as her mother 
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had an HV infection on her lips. Cerebrospinal fluid (CSF) analysis was normal 
(pleocytosis 1x106/l, glucose 4.6 mmol/l, lactate 2.3 mmol/l, and protein 0.16 
g/l). Laboratory investigations showed increased liver transaminases (ALAT 
118 U/l, ASAT 286 U/l). EEG showed generalized slow and high amplitude 
activity, epileptic slow spike-wave complexes and also triphasic waves, which 
are thought to be characteristic of herpes encephalitis. Brain MRI showed a 
diffuse high signal of white matter in periventricular regions, as well as foci of 
high intensity in the basal ganglia (capsula interna, globus pallidus). This 
finding did not affirm HV encephalitis, but Reye syndrome was possible. 
Concurrent brain CT was considered normal. Both Reye syndrome and viral 
infection (HV), however, remained clinically probable. Therefore treatment 
with acyclovir and antibiotics was begun. Treatment of her seizures was 
performed with phenobarbital instead of valproic acid, considering increased 
liver transaminases and hepatomegaly. 
On the 3rd day of hospitalization, liver transaminases were maximally 
increased (ALAT 2232 U/l, ASAT 1594 U/l), but later reduced to the normal 
level. LDH was also increased 1846 (normal range <615 U/l) and ammonia was 
67 (normal range <48µmol/l). There was a reversible coagulation problem — 
prothrombine activity was low: 29% (normal range 70–130%), prothrombine 
INR was high: 1.89 (normal range 0.85–1.25) and antithrombine factor III was 
low: 52% (normal range 80–120%). 
On the 4th day of hospitalization, brain CT showed prevalent diminution of 
the intensity of white matter and diffuse brain edema. The PCR reaction of CSF 
for HV 1 and 2 was negative, as also were immunoglobulins G and M for HV1 
and HV2. No other microbes or fungi had not been found in the blood or CSF. 
Therefore HV encephalitis and the possibility of any other infectious disease 
was excluded. Reye syndrome with unknown origin remained the main/only 
clinical diagnosis. 
After 10 days her condition worsened — the cough reflex as well as reaction 
to pain and aspiration disappeared. The pupil reflex was very weak. Repeated 
brain MRI showed foci with high signal intensity in the basal ganglia region and 
in the occipital area as a subject of the ischemic damage due to persistent brain 
edema. She remained in a deep coma and died one month and three weeks later 
due to cardiac arrest. 
On the 2nd week of hospitalization a liver biopsy was performed and the 
material for electron microscopic investigation was collected. In hepatocytes, 
electron microscopic investigation showed extensive glycogen storage in the 
cytosol. In the lysosomes, heterogeneous and various size vacuoles filled with 
glycogen granules were found. The endoplasmatic reticulum only had free 
space for functioning that amounted to 10–15% of the total cytosol. The 
structure of mitochondrions was changed; there were giant mitochondrions and 
paracristalline structures in mitochondrions. No cholestasis and lipid 
accumulation were found in hepatocytes, but there were lipid granules and 
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hemosiderine inclusions in Kupffer cells. A lot of neutrophils were between 
hepatocytes and in capillaries, and perivascular tissue showed some fibrotic 
changes. These findings are typical of energy production failure in either the 
primary or secondary respiratory chain, or to the glycogenoses. These findings 
are not typical to Reye syndrome, as in the case of Reye syndrome there is 
usually liver steatosis or swallowing of mitochondrions. 
At autopsy the only significant findings in the systemic examination were 
petechias on the upper side of the diaphragm, under the capsule of both kidneys, 
and on the mucosa of the larynx, trachea and bronchi. The kidneys and the liver 
were flaccid, and the section surface of the liver was fawn-colored. The most 
striking finding on gross inspection of the brain was its size and consistency — 
the brain was small (896g (normal 1150g)) and flaccid. The gyri were flattened, 
the sulci narrow, the blood vessels of the meninges congested, and on the 
surface of the cerebellum there was only a mild impression from the 
strangulation. Sections from various locations of the brain were frozen, and the 
remainder was fixated in formalin. 
Pathohistological specification affirmed an acute purulent bronchitis, a 
chronic interstitial nephritis, a polycystic ovarian degeneration and a 
disseminated fatty degeneration of the liver in our patient. 
Macroscopically, there were clots in the venous sinuses of the dura (taken 
for histological specification), and the blood vessels of the leptomeninges were 
slightly congested. On the basal surface of both temporal lobes and the left 
occipital lobe, there were extensive indrawn flaccid areas of collapsed brain 
tissue. All lateral ventricles were dilated; the entorhinal cortex area was 
shrunken and yellow. The medial part of the temporal lobes was softened and 
grizzle-brown in color. In these areas the cortex was very thin with microgyri, 
and the white matter underneath the cortex was friable and easily breakable. An 
unusually large epiphysis with cystic degeneration was noticed. 
Histological investigation verified the thrombosis of the sinus sagittalis. 
Sections from the frontal cortex showed normal neuronal layering and 
lamination, but extensive areas of ruined neuronal layering with only solitary 
preserved neurons and widespread astrogliosis throughout the whole frontal 
cortex without clear demyelination of white matter was stated. Unharmed areas 
from temporal lobes had a subjectively normal architecture and number of 
neurons, but previously macroscopically described dorsal and medial parts 
showed extensive areas of necrosis with intensive macrophagous infiltration, 
gliosis, and Alzheimer type II astrocytosis. On the right, there was a softened 
area at the border of the temporal and occipital lobes where, in addition to 
encephalomalacia, extensive deposition of calcifications throughout the cortex 
was found. The basal ganglia showed intensive necrosis bilaterally, and 
extensive gliosis was found in both hippocampi, with almost vanished 
pyramidal cells beginning from the CA 2 region. There were old and recent 
necrotic areas in the right thalamus, as well as abundantly Alzheimer type II 
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astrocytes, although the epiphysis seemed to be of normal structure. The 
mediodorsal parts of the occipital lobes revealed almost vanished cortex tissue 
with proliferous macrophages and gliotic callus, as white matter showed gliotic 
changes and a spongiform constitution. Small softened areas with macrophages 
and gliosis were found in the ventral mesencephalon and also around the 
aqueduct. The substantia nigra was preserved and of normal structure. In the 
brainstem, the grey and white matter were intermittently laminated, and 
ischemic lesions of neurons were found. Cerebellar neurons had ischemic 
changes with Bergmann’s gliosis, and some lessening in the amount of neurons 
and Purkinje cells in the dental nucleus was noticed. Extensive ischemic 
alterations were found in otherwise normally structured olivary nuclei. 
 Valproic acid, the most effective AED in AS seizure disorder (Viani et al., 
1995; Laan et al., 1997; Buoni et al., 1999; Valente et al., 2006), seems to be 
well-tolerated and is widely used alone or in combination with the other(s) 
AED(s) in epilepsy patients with AS. However, in 2004 Deda et al. described a 
case of reversible toxic hepatitis in a 2-year-old boy with AS and Lennox-
Gastaut syndrome after valproic acid and lamotrigine comedication. Un-
fortunately, no pathohistological findings were presented in this case. Our 
patient had slight metabolic acidosis, elevated ammonia and ALP even before 
the treatment with valproic acid, and showed a fluctuating persistence of these 
laboratory abnormalities during the treatment period. It is possible that valproic 
acid treatment could lead to subacute hepatic failure, and concomitant fever 
management with acetaminophen, one of the most common medications 
causing drug-induced hepatic toxicity in children (Pineiro-Carrero and Pineiro, 
2004), aggravated the situation to the critical Reye-like illness. Her clinical 
problems on admission most closely resemble a valproate-induced hyperam-
monemic encephalopathy (VHE) — a decreased level of consciousness, low-
grade fever, and an increase in the frequency of seizures. On admission she 
demonstrated EEG findings characteristic not only to herpes-encephalitis, but 
also to VHE — triphasic waves and, moreover, the brain MRI showed a diffuse 
high white matter signal of the periventricular regions, foci of high intensity in 
the basal ganglia (capsula interna and globus pallidus), the findings described in 
VHE (Ziyeh et al., 2002). The function of the UBE3A in the pathogenesis of AS 
is poorly understood. Ubiquitin-mediated proteolysis is regarded as the major 
pathway by which most intracellular proteins are destroyed (Ciechanover, 
2001). From the toxicological standpoint it is equally important that the 
ubiquitin-proteasome system is also widely considered to be a cellular defense 
mechanism, since it is involved in the removal of damaged proteins generated 
by adduct formation and oxidative stress (Donohue, 2002). Our case emphasizes 
the possibility that patients with AS who lack maternally imprinted UBE3A 
tissue specific expression, may be more prone to hepatic problems. Our patient 
likely died of a combined idiosyncratic valproic acid and acetaminophen 
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hepatotoxicity with Reye-like syndrome, which was complicated by malignant 
brain edema and edema-induced ischemic lesions in the brain. 
 To our knowledge, only two AS autopsy cases have been published (Jay et 
al., 1991; Kyriakides et al., 1992) to date: a 21-year-old female and a 2y 10m 
old boy. In these cases the diagnosis of AS was based on clinical findings alone. 
The young adult died from recurrent pneumonia and pulmonary abscess, and the 
child experienced SUD (probable asphyxia, secondary to a seizure). The most 
striking findings from the autopsy of the female were: a small brain, marked 
cerebellar atrophy with loss of Purkinje and granule cells and extensive 
Bergmann’s gliosis, as well as a marked decrease in the dendritic arborization 
of layer 3 and 5 pyramidal cells of the visual cortex (Jay et al., 1991). The 
major neuropathological findings in the boy were macroscopic and consisted of 
a small brain, truncated temporal lobes and relatively small frontal lobes with 
poorly delineated gyri (Kyriakides et al., 1992). Our patient, 3y 7m, had a small 
brain, extensive edematous-ischemic lesions with necrosis and gliosis, Alzhei-
mer type II astrocytosis of temporal lobes, hippocampal gliosis with almost 
completely destroyed hippocampal pyramidal cells, and also cerebellar atrophy 
with concomitant unobtrusive lessening in the amount of Purkinje cells and 
Bergmann’s gliosis. The autopsy findings of MM indicate three different patho-
logical changes: chronic edematous-ischemic, chronic hepatic failure, and also 
alterations of AS. In the case of chronic liver failure, the astrocytes, the neural 
cells most vulnerable to hepatic failure, undergo characteristic changes known 
as Alzheimer type II astrocytosis (Hazell and Butterworth, 1999), and these 
changes were present in our case in the thalamus and in the medial parts of the 
temporal lobes. However, the only similarity connecting these three deceased 
patients with AS is microcephaly (typical for AS?), whereas the patient 
described by Jay et al. (1991) and our patient showed cerebellar atrophy with a 
decreased number of Purkinje cells (long term AED?/link to truncal ataxia?) 
and Bergmann’s gliosis (a regular accompaniment of anoxic/ischemic injury 
and other conditions associated with the death of Purkinje cells). More 
morphological studies are necessary to elucidate the enigmatic pathogenesis and 
the involvement and susceptibility of different organ systems in AS. 
 
 
5.2.3. Clinical phenotype of PWS 
 
5.2.3.1. Phenotype of patients with PWS (publication III, IV) 
 
A total of 12 patients with PWS were diagnosed among children born between 
1984 and 2004; one girl (del 15q11-13) died before the study period, and one 
boy (Robertsonian translocation 15q;15q) was lost for follow-up before 
molecular genetic studies were completed. Ten patients (3 boys, 7 girls) were 
diagnosed during the study period (2000–2004). The overall diagnostic 
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frequency was 11% (10 cases out of 91 suspected subjects), but considering 
only the subjects born between 2001–2004 (prospective group), the diagnostic 
frequency was 33% — of 15 suspected patients, five were positive for PWS. 
The mean age at diagnosis was 4.3 years, but since 2000 all children were 
diagnosed in infancy, and the last three patients in their first week of life. Two 
recent studies reported the mean age at diagnosis for PWS being between 5y 4m 
(del) and 6y 2m (UPD) (Varela et al., 2005), or between 3.86 y (del) and 3.89 y 
(UPD) (Torrado et al., 2006), indicating that new and reliable diagnostic 
possibilities could play an important role in much earlier diagnosis than was the 
case years ago. Moreover, a systematic search for certain patients and quick 
diagnostic work-up can serve as a good training tool for neonatologists/  
physicians to recognize relevant patients, and our low mean age at diagnosis of 
PWS is a good example of this. 
 After birth, all patients were hospitalized from maternity hospital to the 
children’s hospital due to insufficient arousal and muscular hypotonia of 
unknown etiology. Early diagnosis of five consecutive patients with PWS 
allowed us to study in detail the peculiarities of the neonatal period in PWS. All 
neonates showed marked central muscular hypotonia (Figure 4), insufficient 
arousal, almost absent or weak crying, no interest in food, transient bradycardia 
(110–70 beats per minute) and thermolability (incubator care for hours/days), 
pale and/or intensely mottling skin with acrocyanosis, and needed aided feeding 
for several weeks/months (Table 10). During the first two or three days of life, 
congenital and deep tendon reflexes were difficult to elicit. In addition, all five 
had a distinctive facial appearance — a high prominent forehead, a narrow 
bifrontal diameter, downturned corners of the mouth, micrognathia and 
dysplastic ears (Figure 5). Three neonates had a high-arched palate and four out 
of five demonstrated arachnodactyly. We also noticed a peculiar position of the 
thumbs during the first days of life — patients 2–5 constantly held their thumbs 
adducted over the index and middle finger, and sometimes even over the ring 
finger (Figure 6). Two of our five newborns had signs of hypogenitalism — the 
male patient had bilateral cryptic testes and one female had hypoplastic labiae 
majora. Two patients with UPD demonstrated a delay in passing meconium, and 
spontaneous defecation occurred on the 6th and 3rd day respectively. Two 
patients with deletion revealed cephalhematomas after birth.  
 The first major consensus diagnostic criterion of PWS is neonatal central 
hypotonia with poor suck, which gradually improves with age (Holm et al., 
1993). All of our patients had central hypotonia, poor suck during the first few 
weeks/months of life and feeding difficulties. It is not entirely clear whether the 
poor suck (inability to suck and swallow) is due to an immaturity of the sucking 
reflex, insufficient arousal, muscular hypotonia, lack of interest in food or a 
combination of all of these. 
 The facial appearance of neonates with PWS has been subject to debate for 
many years. Some authors reported subtle or absent facial dysmorphy (Aughton 
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and Cassidy, 1990; Miller et al., 1999), whilst others considered facial features 
to be relevant for the diagnostic process (Stephenson, 1980; Chitayat et al., 
1989; Trifirò et al., 2003). Recently, Trifirò et al. (2003) reported that 12 out of 
21 infants with PWS presented at least three different craniofacial features 
(almond-shaped eyes, small palpebral fissures, narrow bifrontal diameter, 
micrognathia, low-set ears, a long philtrum, a thin upper lip, dolichocephaly, a 
downturned mouth), and that seven infants were clinically diagnosed with PWS 
as neonates. All of our newborns with PWS were photographed to document 
and investigate the facial features. The comparison of the photographs reveals 
striking similarities and a recognizable facial phenotype — a high prominent 
forehead, a narrow bifrontal diameter, downturned corners of the mouth, 
micrognathia and dysplastic ears, regardless of the genetic etiology of the 
syndrome (Figure 4A-E). To our knowledge there have to date been only a few 
reports documenting the facial features of newborns with PWS using 
photographs (Stephenson, 1980; Matsumura et al., 2003; Klein et al., 2004). We 
found that photographs were extremely helpful in recognizing facial phenotype. 
Furthermore, our patients have demonstrated a similarity in facial gestalt to the 
previously described cases of newborns with PWS. 
 Denizot et al. (2004) reported on a case of distal arthrogryposis in a newborn 
with PWS, and Klinge et al. (2001) described a newborn who tended to hold 
both thumbs adducted, although they did straighten on passive movements. In 
our study, four of five newborns with PWS constantly held their thumbs 
adducted over the I and II fingers, and sometimes even III finger (Figure 6). The 
same phenomenon was seen on two photographs of newborns with PWS at the 
age of 3–4 weeks published by Stephenson (1980). In addition, there were 
several nonspecific descriptions of PWS newborns’ hands as flexed wrists and 
paralyzed distal parts of the hands (Aughton and Cassidy, 1990). The specificity 
of this finding for PWS needs further clarification. In addition, the acceptance 
of small hands and feet as the criteria for PWS (Holm et al., 1993) might be 
confusing in neonatal age. In contrast, long and/or tapering fingers have been 
described (Chitayat et al., 1989; Aughton and Cassidy, 1990), and in our study 
group four out of five newborns had arachnodactyly as a remarkable symptom. 
 Another controversial issue in PWS is the presence of neonatal respiratory 
distress. Some authors have described birth asphyxia in 23% of patients with 
PWS (Wharton and Bresnan, 1989), but others found neither perinatal asphyxia 
nor severe respiratory distress after birth (Trifirò et al., 2003). All of our 
patients were born with an Apgar score of 7 or more immediately after birth and 
also at 5 minutes. There may be a predisposition to mild birth asphyxia, 
respiratory distress or apnoic spells in PWS (Chitayat et al., 1989; Yoshii et al., 
2002; Horsthemke et al., 2003; Denizot et al., 2004). Wharton and Bresnan 
(1989) have pointed out that asphyxiated babies did not differ from their peers 
in terms of pregnancy duration, position in utero or fetal movements, but others 
noted that respiratory distress or apnoic spells were related to prematurity or 
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were present in babies who were small for their gestational age (Chitayat et al., 
1989; Yoshii et al., 2002; Horsthemke et al., 2003; Denizot et al., 2004). A 
similar correlation was seen in our patient 2 (Table 10), who was small for her 
gestational age (40 wks/2316 g) and demonstrated apnoic spells. Due to severe 
hypotonia and often abnormal presentation in utero, babies with PWS could be 
predisposed to birth asphyxia and may also have hypoxic-ischemic brain 
damage. Recognizing postnatal signs not related to hypoxic birth-insult could 
assist in establishing an accurate diagnosis of PWS. 
 All of our patients (5/5) demonstrated thermolability and acrocyanosis, and 
three of them also intense skin mottling. Williams et al. (1994) proved that 
abnormal temperature regulation in patients with PWS, compared with other 
neurodevelopmentally handicapped individuals, is a perceptual bias, but during 
the neonatal period, the coexistence of profound hypotonia, bradycardia and 
thermolability is a valuable marker for the identification of patients with 
probable PWS. Chitayat et al. (1989) has also pointed out cold extremities and 
skin mottling, and all of the newborns in our study group were pale and/or 
demonstrated intensely mottling skin. 
 The minor criteria of PWS include decreased fetal movements or infantile 
lethargy or weak cry in infancy, improving with age (Holm et al., 1993). The 
vast majority of investigators have dealt with absent or weak abnormal cry in 
neonates with PWS (Chitayat et al., 1989; Wharton and Bresnan, 1989; 
Aughton and Cassidy, 1990; Holm et al., 1993; Miller et al., 1999), while 
lethargy, insufficient arousal or hypersomnolence have been only sparsely 
mentioned (Hoefnagel et al., 1967; Wharton and Bresnan, 1989; Yoshii et al., 
2002). Nevertheless, weak or absent cry seems to be a consequence of 
insufficient arousal. In addition, the controversy in assessing congenital reflexes 
may be explained by the different time of examination (Hoefnagel et al., 1967; 
Stephenson, 1980; Miller et al., 1999; Klinge et al., 2001). Our experience with 
neonates showed that all of the babies were severely depressed after birth, so 
congenital and deep tendon reflexes during the first two or three days of life 
were released with latency or were difficult to elicit, but later were normal or 
even slightly exaggerated. 
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Figure 6. 
 
 
According to our results and the previously published data, the main diagnostic 
criterion of PWS is neonatal hypotonia, but it’s differential diagnosis comprises 
a broad spectrum of disorders. According to Paro-Panjan and Neubauer (2004), 
the diagnostic approach to floppy infant consists of a detailed history and 
clinical evaluation as the first step, neuroimaging techniques as the second step, 
Oxford Medical Data as the third step, karyotyping and FISH for PWS as the 
fourth step, biochemical tests as the fifth step and specific investigations of 
muscle and nerve as the sixth step. However, Richer et al. (2001) suggested a 
more flexible schedule of investigations, based on family history, case evalua-
tion and clinical findings, and the next step consisting of neuroimaging, EMG/ 
NCS and/or specific genetic tests. They also recommended that a profoundly 
hypotonic neonate without electrophysiological abnormalities could be an 
object for DNA methylation testing for PWS. The results of our study suggest 
using the DNA methylation test even before EMG/NCS if the full described 
complex of symptoms in a term neonate is present. The DNA methylation 
analysis is a reliable primary and time-saving test covering the most frequent 
causes of PWS (up to 99%) and by using its advantages we were able to make 
the diagnosis as early as in the first week of the patient’s life. For a patient and 
his/her family, this is undoubtedly the best solution, and saves them from 
unnecessary/painful tests and investigations, but it is also cost effective. Three 
of five newborns of our study group had UPD, and using the schedule proposed 
by Paro-Panjan and Neubauer (2004) and the FISH analysis as the primary test, 
we may have lost 60% of diagnoses, at least for some time. 
 All six patients with PWS who were born before 2000 were hospitalized in 
the neonatal care unit due to marked muscular hypotonia, feeding difficulties 
and apparent arousal insufficiency (Table 11). Two mothers out of six suffered 
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imminent miscarriage, two children were born in breech presentation, one 
mother suffered from hyperthyroidism during pregnancy; one mother with twins 
showed an increased level of 17-OH progesterone and was treated with 
prednisolone. Only one pregnancy was uncomplicated. Two children were 
preterm (34 wks; 33wks) and one was small for gestational age (38wks/1900g). 
Brain US showed different problems in three out of six neonates, one child had 
neonatal seizures and one demonstrated a marked neonatal tremor. They all 
needed assisted feeding, and the shortest duration of tube feeding was 17 days. 
Independent walking appeared after 18 months of age in all children. The mean 
age of unsupported walking was 20 months, while independent walking 
normally begins between 13 and 15 months. One subject (TP) had febrile 
seizures, and two others had abnormal EEG. Four out of six (67%) showed mild 
brain atrophy on CT/MRI: two had mild frontal atrophy and two mild 
ventriculomegaly. Bone age by TW-RUS deviated in four children: in one case 
it was accelerated by one year, whereas three others showed a delay of six 
months to 1 year. The onset of excessive weight gain was observed relatively 
late, at mean age of 3 years, which may be explained by the fact that two 
children were on a low protein diet during their first three years of life. Two 
older subjects were severely obese (BMI >40), three slightly overweight (BMI 
25.0–29.9), and the youngest girl had a normal BMI. Adenoidectomia was 
performed in three patients. Four subjects showed various cardiovascular 
problems including decreased myocardial contractility, prolonged PQ time, 
suspected incipient cardiomyopathy, and FOA with mitral valve prolapse. 
Vision problems were noticed in four patients. 
 Using consensus diagnostic criteria, all patients collected 13 and more 
points; the mean score for six subjects was 13.6 points. None of our patients 
demonstrated thick viscous saliva, skin picking was a problem for only one 
individual, and there was no evident scoliosis or kyphosis. We observed 
frequent abnormalities in brain US in the neonatal period, and later the brain 
MRI/CT was abnormal in 67% of cases (4 patients out of 6), with two children 
having an abnormal EEG. The incidence of cardiovascular problems was 
surprisingly high (67%; 4 patients out of 6). The same percentage of patients 
showed deviations from normal bone maturation/bone age. 
 The neuropathologic defects associated with PWS are still largely unknown, 
and there have only been a few studies on brain abnormalities in PWS (Miller et 
al., 1996; Hashimoto et al., 1998; Klinge et al., 2001; Yoshii et al., 2002). Only 
recently Miller et al. (2006), using three dimensional MRI scans, showed 
ventriculomegaly in all, decreased volume of brain tissue in the parietal-
occipital lobe in 50%, sylvian fissure polymicrogyria in 60%, and incomplete 
insular closure in 65% of subjects with PWS. We found mild ventriculomegaly 
or mild frontal atrophy in four out of six patients (67%) with PWS, although the 
origin of these abnormalities remained unknown — they might be a 
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consequence of dysontogenesis or complication of birth asphyxia induced 
hypoxic-ischemic changes. 
 Interestingly, no one in our study group had epilepsy, but two patients 
demonstrated abnormal EEG; slow background activity was found in one and 
bursts of spike waves in the other. It has been shown that patients with PWS 
and deletion tend to have epileptic seizures (Varela et al., 2005; Wang et al., 
2005), but Wang et al. (2005) also detected EEG abnormalities in patients with 
PWS without epilepsy. Moreover, Wang et al. (2005) found that 20% of study 
subjects (both with and without seizures) had EEG features of persistent high-
amplitude 4–6 Hz activities resembling a pattern typical of AS. 
 The ongoing discussion about SUD has raised questions about the still 
unknown or poorly understood features of PWS posing a vital risk. Disturbance 
of central respiratory control and hypoventilation probably are involved in the 
genesis of SUD, but the time of death being early in the morning (a normally 
high level of cortisol) and some autopsy cases showing adrenal hypoplasia 
(Stevenson et al., 2004) also suggest a role for adrenal insufficiency in PWS. 
Cardiomyopathy has been reported in individuals with larger than usual 
chromosome 15 deletion (Ahmad et al., 2001), cardiac alpha actin gene (ACTC) 
disruption at 15q14, but also in patients with common deletions in PWSCR and 
UPD (Schrander-Stumpel et al., 2004; Stevenson et al., 2004; Nagai et al., 
2005). As noted above, four out of six patients in our study group had different 
cardiovascular problems. Excess secretion of GH has been connected with 
increased soft tissue thickness and with sleep apnea (Gerard et al., 1997), but 
hypertrophy of the tonsils and adenoids have been reported in patients with 
PWS with and without GH treatment (Grugni et al., 2005). Three patients 
(50%) in our study group had adenoidectomia, two of them had UPD, and one 
had deletion. Therefore we would like to emphasize that all children with PWS 
need careful medical supervision that should include cardiovascular monitoring 
and otorhinolaryngological examination. We suggest that all children with PWS 
should undergo an interdisciplinary medical observation at least once a year and 
always before and during GH treatment. More detailed studies are needed to 
elucidate the role of different organ systems in critical illness and early death in 
PWS. 
 Several correlation studies between genotypic variants and different mani-
festations have been performed (Robinson et al., 1991; Mitchell et al., 1996; 
Cassidy et al., 1997b; Gunay-Aygun et al., 1997a; Webb et al., 2002; Varela et 
al., 2005). Most of these authors agree that individuals with deletion or UPD do 
not present significant differences in anthropometric measurements, neonatal 
hypotonia, hypogonadism and hyperphagia, but data for certain traits such as 
characteristic faces, IQ scores and behavioral problems are inconclusive. As our 
study group was small and five out of the twelve children were younger than 3 
years old, we cannot give a reliable comparison between different subgroups. 
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5.2.3.2. Severe PWS phenotype and unusual additional problems 
 
Most deletions causing PWS are interstitial, but approximately 1% of the 
patients have de novo unbalanced structural rearrangements involving the 
proximal 15q region (Nicholls et al., 1998). 
Case report of IB. Patient IB (Table 10, patient 4), the first daughter of a 
healthy 18-year-old woman, was born at 42 weeks of gestation. Her birthweight 
was 2700 g (-1.5 SD), length 53 cm (+1 SD), HC 35 cm (0 SD) and Apgar 
scores 7/8. She showed insufficient arousal, severe muscular hypotonia, 
bradycardia and thermolability. At 16 hours of life she started to keck and was 
admitted to the neonatal intensive care unit. Dolichocephaly, a small anterior 
fontanelle, a prominent nasal bridge, a beaked prominent nose, inward obliquity 
and slight hypertrophy of the alveolar ridges, microretrognathia, low set 
dysplastic ears, a long neck, arachnodactyly, slight camptodactyly of the II, III 
and IV fingers, a particular position of the thumbs overlapping the third fingers 
and long nails were noted (Figure 4D, Figure 5D, Figure 6). Cardiovascular 
examination revealed FOA and DAP. Tube feeding was discontinued at the age 
of three months. At the age of 8 months her psychomotor development was 
markedly delayed — she had no proper head control, and she was only able to 
turn to the side when in the spine position. Her psychomotor development 
corresponded to the age of 3 months. Brain MRI at the age of 8 months showed 
mild brain atrophy and some patchy gray matter areas close to the lateral 
ventricles, and subependymal heterotopia was diagnosed. The girl had an 
unbalanced translocation of chromosomes 14 and 15 resulting in a deletion of 
chromosome 15p13-q13. Using FISH, the deletion included the PWS critical 
region and BAC clone RP11–463i22, karyotype 45,XX,der(14)t(14;15) 
(p11;q13).ish der(14)t(14;15)(D14Z1/D22Z1+,D15Z1–,SNRPN–,bac463i22/ 
AQ634845–,PML+,yac895h10+). Clone RP11–463i22 corresponds to the 
segment from 25,725 to 25,892 Mb on chromosome 15 (UCSC Genome 
Browser, May 2004 assembly). The distal end of the typical 15q11-13 deletions 
in PWS and AS is defined by BAC RP11–48j4 (http://www.sanger.ac.uk/ 
PostGenomics/decipher), which spans from 24,346 to 24,490 Mb on chromo-
some 15 (UCSC Genome Browser). Hence this girl had a deletion at least 1.4 
Mb larger than typical 15q11-13 deletions (Butler et al., 2004). 
Several cases of familial and de novo balanced or unbalanced translocations 
have been reported, but only two case reports describe translocations involving 
chromosomes 14 and 15. Smith and Noël (1980) reported on a Robertsonian 
translocation t(14;15) in a mother and three of her seven children. One of them, 
a girl with the karyotype of 45,XX,t(14;15)(p11;q11), had the classical 
phenotype of PWS. Hasegawa et al. (1984) described a family with the 
reciprocal translocation of the chromosomes 14 and 15, which was detected in 
three family members: the mother, the maternal grandmother, and a maternal 
uncle of the proband. The proband and one of the first cousins had an 
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unbalanced translocation as 46,XY or XX,-15, + der(14),rcp(14;15)(q11.2;q13). 
They had a partial trisomy of the 14pter leads to the q11.2 segment and a partial 
monosomy of the 15pter leads to the q13 segment. The clinical features 
observed in both cousins were pale complexion, oxycephaly, a flat occiput, a 
very small forehead with narrow bifrontal diameter, thick hair and eyebrows, a 
beaked nose with a broad and flaring nasal bridge, poorly modeled ears, a 
hypoplastic maxilla, prognathism, a triangular mouth, a thin upper lip, a high-
arced palate, abnormal dentition, small hands and feet, clinodactyly of the fifth 
fingers, hypoplastic genitalia, severe hypotonia and profound mental 
retardation. The boy (10y) was overweight and the girl (5y) was proportionally 
small for her age. Brain CTs were unremarkable; the boy had myoclonic 
seizures and abnormal EEG. However, since no DNA analysis was performed 
in these two cases, it is unknown whether the clinical phenotype was a 
consequence of maternal or paternal monosomy of the PWS/ASCR, as they 
both showed the clinical phenotype that overlaps with AS. An unbalanced 
translocation, including the deletion of the centromere of chromosome 15 and 
the proximal part of the short arm together with the deletion of PWSCR, seems 
to be extremely rare, as we did not find any similar cases in the literature. Also, 
we are not aware of previously published cases of a larger deletion involving 
the centromere and 15p13. Nevertheless, there is no clear evidence of functional 
genes proximal to the common PWS deletion breakpoints, and therefore it has 
been assumed that genes involved in the additional symptoms of the reported 
cases are located within the common BP3 and the distal end of the described 
deletions (Krajewska Walasek et al., 1998; Smith et al., 2000; Matsumura et al., 
2003; Windpassinger et al., 2003; Varela et al., 2004a). However, our patient 
IB showed disproportionate intra-uterine growth, a prominent nasal bridge, a 
beaked prominent nose, inward obliquity and slight hypertrophy of the alveolar 
ridges, microretrognathia, low-set dysplastic ears, a long neck, slight 
camptodactyly of the II, III and IV fingers, FOA, DAP, marked psychomotor 
developmental delay, and subependymal heterotopia not ascertained as a 
classical PWS phenotype. Nevertheless, the origin of her “severe” PWS 
phenotype remains unclear, as in translocation cases, the imbalance of the 
derivative chromosome involved in the translocation could be another cause of 
the different/complicated phenotype. 
 In one patient with PWS (Table 11, TP), the X-linked ichthyosis due to 
steroid sulfatase (SS) deficiency was also diagnosed. He has a positive family 
history for X-linked ichthyosis: his older brother had the same problem. It has 
been shown that approximately 90% of patients with SS deficiency have a 1.9 
Mb deletion on Xp22.3, the region susceptible to chromosomal rearrangements 
mediated by VNTR-like repeats flanking the deletion interval and resulting in 
complete deletion of the SS gene (Ballabio et al., 1989; Yen et al., 1990). 
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5.2.3.3. Sudden death (publication V) 
 
Patient MK suffered a cardiac arrest during an episode of recurrent bronchitis at 
the age of 3 years and 6 months  
Case report of MK. She was the first child of non-consanguineous parents 
and was born at term (Table 11). The labor was complicated: there was a period 
of 15 hours without amniotic fluid, and the umbilical cord was found to be 
around the neck and body. Her birth weight was 3000 g, length 52 cm and 
Apgar score 7/8. From the first hours of life she demonstrated severe hypotonia, 
lethargy, a weak cry and feeding problems, and needed treatment in a neonatal 
care unit. Her initial diagnosis was hypoxic-ischemic encephalopathy. 
Feeding difficulties, failure to thrive, hypersalivation and marked hypotonia 
persisted. At seven months of age thorough clinical investigations were 
performed, but did not yield helpful results. An unspecified metabolic disorder 
was suspected, and a strict protein limitation (1.5 g/kg) in daily food intake was 
started ex iuvantibus. Her motor milestones delayed: head control was achieved 
at 4 months, crawling at 13 months and independent steps at 19 months. Brain 
CT at 17 months of age indicated mild ventriculomegaly with no focal 
abnormalities in the brain tissue. Upon clinical and metabolic evaluation at the 
age of 2 years, the low protein diet was discontinued. Shortly after that she 
developed an insatiable appetite and rapidly gained weight. At the age of 2 
years 10 months she was seen by a clinical geneticist. She was severely obese 
(weight 25.5 kg, +5.5 SD) with normal height (97 cm, +1 SD) and HC (49.5 cm, 
0 SD). Facial features included almond-shaped palpebral fissures, epicanthal 
folds, narrow bifrontal diameter, a small nose and a thin upper lip. Her hands and 
feet were small. Moderate muscular hypotonia and mild developmental delay were 
noticed. PWS was suspected, and FISH revealed the 15q11-q13 deletion. 
At 3 years of age she developed excessive daytime sleepiness with frequent 
narcolepsy-like attacks, breathing disturbances and recurrent bronchitis. At 3 
years 6 months, during an episode of bronchitis, she suffered a cardiac arrest 
during early morning sleep. After resuscitation she remained in a chronic 
vegetative state. CT imaging showed extensive brain tissue hypodensities in the 
frontal and temporal lobes, especially in the basal areas, moderate hyperdensity 
of the thalamus and middle structures, and bilateral marked symmetrical hyper-
densities in the globus pallidus. The latter findings were initially interpreted as 
calcifications of the basal ganglia, but retrospectively were thought to represent 
hypoxic-ischemic brain lesions with bilateral symmetrical hemorrhages in the 
basal ganglia. She died two months later. The parents refused an autopsy. 
This was the first report of a chronic severe breathing disturbance in a child 
with PWS, which in combination with acute recurrent bronchitis preceded a 
cardiac arrest. We were aware of only two previous reports on early deaths in 
PWS, and most of these patients had a short history of a febrile infection that 
took a very rapid course (Clericuzio et al., 1997; Schrander-Stumpel et al., 
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1998). In our case, the history of bronchitis was in line with the previous 
reports, but we wanted to emphasize the pre-existing marked breathing disorder. 
Apnea and chronic hypoventilation are well-known causes of hypoxia, 
hypercapnia and cor pulmonale. In PWS, the severity of nocturnal oxygen 
desaturation correlates with the degree of obesity (Hertz et al., 1995). 
Ventilatory failure and cardiorespiratory distress may develop after massive 
weight gain, and can progress rapidly (Cadle and Hall, 1989). Our patient also 
became extremely obese within one year, with narcolepsy-like attacks and 
breathing disturbance. 
Based on the recurring CT findings, her brain lesions most likely evolved 
between the age of 1y 5m and 3y 6m. The lesions may be explained by the 
chronic hypoventilation or the cardiac arrest. Their bilateral and symmetrical 
spatial distribution could possibly indicate that in PWS the basal ganglia may be 
especially vulnerable to hypoxemia. Few reports have focused on specific brain 
abnormalities in deceased patients with PWS, and reported findings have been 
heterogeneous (Hattori et al., 1985; Hayashi et al., 1992; Reske-Nielsen and 
Lund, 1992; Swaab, 1997; Stevenson et al., 2004). Hattori et al. (1985) reported 
on the disturbed undulating structures in the dentate nucleus, ectopia of Purkinje 
cells in the molecular layer and the heterotopia of middle-sized neurons in the 
cerebellar white matter in a 23-year-old male. Hayashi et al. (1992) described 
almost the same abnormality in a 6-month-old girl — disturbance of the 
undulating structures in the dentate nucleus and the inferior olivary nucleus, as 
well as a grumose degeneration of the nerve cells in the dentate nucleus. In an 
autopsy of 16-year-old boy, Reske-Nielsen and Lund (1992) found extensive 
calcifications in the leptomeninges, the first and second layer of the cerebral and 
cerebellar cortex, and along the ventricular system. Examination of the basal 
ganglia revealed calcified nerve cells and lumps of encrustations and lime salts 
in the vessel walls (Reske-Nielsen and Lund, 1992). These latter observations 
(Reske-Nielsen and Lund, 1992) are in line with our hypothesis that the basal 
ganglia may be especially susceptible to hypoxic stress in PWS. 
Until 2000, the early death of PWS subjects had only been reported twice 
(Clericuzio et al., 1997; Schrander-Stumpel et al., 1998). Recently, widely 
introduced GH treatment and successively reported cases of SUD during the 
first months of treatment have raised the issues of the relationship between GH 
treatment and SUD and the importance of extreme critical illnesses in PWS 
(Eiholzer et al., 2002; Nordmann et al., 2002; Smith et al., 2003b; Schrander-
Stumpel et al., 2004; Stevenson et al., 2004; Van Vliet et al., 2004; Nagai et al., 
2005). The same causes of death were, however, found in patients with and 
without GH treatment (Schrander-Stumpel et al., 2004; Stevenson et al., 2004; 
Nagai et al., 2005). Our patient never received GH, and her case follows the 
typical pattern of SUD in PWS — central respiratory dysregulation with 
recurrent respiratory infections followed by a cardiac arrest during early 
morning sleep. 
 21
 82
6. CONCLUSIONS 
 
1.   The minimum livebirth prevalence of AS in Estonia is 1:52,181 (95% CI 
1:25,326–1:129,785), and the population prevalence 1:56,112 (95% CI 
1:25,780–1:152,899). 
 
2.   The minimum livebirth prevalence of PWS in Estonia is 1:30,439 (95% CI 
1:17,425–1:58,908), and the population prevalence 1:30,606 (95% CI 
1:17,105–1:61,311). 
 
3.   Our results demonstrate that the livebirth prevalence of AS is 1.7 times less 
than the livebirth prevalence of PWS. This finding differs from previous 
studies showing the seemingly similar prevalence of these syndromes. 
 
4.   We observed a nominal increase in the livebirth prevalence of AS in the 
years 1984–2004, from 0.88 to 4.23 per 100,000 livebirths (p=0.2). The 
increase in the livebirth prevalence of PWS over the same period was more 
pronounced, from 1.13 to 7.97 per 100,000 livebirths (p=0.032). 
 
5.   Genetic investigations of patients with AS confirmed 15q11-13 deletion in 6 
patients and UPD15 in one patient. Six patients with PWS had UPD15, a 
surprisingly high proportion (50%), four patients had 15q11-13 deletion, and 
two had chromosomal rearrangements — a Robertsonian translocation 15;15, 
and an unbalanced translocation with karyotype 45,XX,der(14)t(14;15) 
(p11;q13).ish der(14)t(14;15)(D14Z1/D22Z1+,D15Z1-,SNRPN-,bac463i22/ 
AQ634845-,PML+,yac895h10+). 
 
6.   We found that the coexistence of profound central muscular hypotonia, 
insufficient arousal, no interest in food, transient bradycardia and 
thermolability, peculiar skin appearance, the characteristic facial phenotype, 
and a peculiar position of the thumbs was indicative of PWS in a term 
neonate. The presence of this symptom complex appears to be sufficient to 
justify the DNA methylation-based test as a primary step in diagnostic 
investigations. 
 
7.   The patients with AS were diagnosed later (mean age at diagnosis 6.1 years) 
than patients with PWS (mean age at diagnosis 4.3 years). Early diagnosis 
of AS is complicated by the lack of seminal clinical symptoms in the 
infantile period. 
 
8.   The childhood clinical phenotype of patients with AS and PWS was 
generally similar to previously described patients. The exceptions were 
frequent brain abnormalities and cardiac problems in patients with PWS 
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(67%), and abnormal bone maturation in AS (57%) and in PWS (67%) in 
patients older than 1 year. 
 
9.   In 21% of our study patients we identified health problems not reported 
previously in AS and PWS: a girl with AS demonstrated unusual limb 
deformities, a boy with PWS had X-linked ichthyosis, a girl with 
unbalanced translocation 14;15 resulting in a large deletion of 15p13-q13 
showed severe PWS with additional symptoms, and a girl with AS died 
because of a Reye–like syndrome. 
 
10. We observed two cases of early death in patients with AS and PWS: a girl 
with PWS died suddenly from cardiac arrest during a respiratory infection, 
and a girl with AS died from Reye-like syndrome. 
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SUMMARY IN ESTONIAN 
 
ANGELMANI JA PRADER-WILLI SÜNDROOM EESTIS 
 
Angelmani sündroom (AS) ja Prader-Willi sündroom (PWS) on tänapäeval 
geneetikas tuntud kui õed-sündroomid, sest mõlema sündroomi tekkepõhjuseks 
on muutused 15. kromosoomi pika õla regioonis q11-13. Kõigepealt avastati, et 
PWS on põhjustatud väikesest interstitsiaalsest deletsioonist 15q11-13 regioonis 
(Ledbetter jt., 1980; Ledbetter jt., 1981). Segadus saabus siis, kui selgus, et ka 
AS puhul on patsientide kromosoomianalüüsil võimalik avastada samasugune 
deletsioon (Kaplan jt., 1987; Magenis jt., 1987; Donlon, 1988). Alles RFLP 
metoodika kasutuselevõtt võimaldas eristada kahte deletsiooni — AS põhjustav 
deletsioon asus alati emalt päritud ja PWS deletsioon isalt päritud 15. 
kromosoomis (Butler jt., 1986; Knoll jt., 1989; Nicholls jt., 1989a). AS ja PWS 
esindavad geneetilisi haigusi, mille tekke aluseks on genoomne imprinting 
(vermimine) ehk nähtus, kus geeni(de) avaldumine (ekspressiivsus) sõltub 
geeni(de) ema- või isapoolsest pärinemisest (Nicholls jt., 1989b; Hall, 1990; 
Williams jt., 1990). Molekulaargeneetilisi mehhanisme, mis põhjustavad AS-i 
ja PWS-i on mitu: 15q11-13 piirkonna deletsioon, uniparentaalne disoomia 
(UPD) (mõlemad 15. kromosoomid ühelt vanemalt) (Nicholls jt., 1989b; Knoll 
jt., 1991), defektne vermimine (ID) (Buiting jt., 1995) ning AS puhul ka mutat-
sioonid UBE3A geenis (Kishino jt., 1997; Matsuura jt., 1997; Sutcliffe jt., 
1997). 
 AS kirjeldas esmakordselt inglise pediaater Harry Angelman 1965. aastal kui 
ta artiklis ““Puppet children”: a report on three cases” võttis kokku kolme 
sarnase patsiendi kliinilise leiu ja uuringute tulemused. Kolme patsienti iseloo-
mustasid sügav vaimupuue, kõne puudumine, sarnased näojooned, naeruhood, 
(hüpik)nukulikud liigutused, krambid ja EEG leiu iseärasused. PWS esma-
kirjeldus pärineb John Langdon Downilt, kes 1864. aastal avaldas ühe oma 
patsiendi põhjaliku kirjelduse ning nimetas haigust, mille all patsient kannatas, 
“polysarca” (Down JL, 1864, tsiteering Ward, 1997). Haigus taasavastati kui 
1956. aastal Zürichi arstid Andrea Prader, Alexis Labhart ja Heinrich Willi 
kirjeldasid üheksat ülekaalulist, lühikesekasvulist, krüptorhismi ja oligofree-
niaga patsienti, kes kõik olid olnud varases lapsepõlves hüpotoonilise lihaskon-
naga (Prader jt., 1956). 1993. aastast pärineb konsensus diagnostilistele kritee-
riumitele diagnoosimaks PWS (Holm jt., 1993) ning 1995. aastast konsensus 
AS kohta (Williams jt., 1995). Mõlema sündroomi geneetilist diagnostikat on 
oluliselt lihtsustanud DNA metülatsioonispetsiifilise PCR metoodika juuruta-
mine (Driscoll jt., 1992; Kubota jt., 1997; Zeschnigk jt., 1997). DNA metülat-
sioonitest sobib patsientide esmaseks uuringuks, kuid ei erista erinevaid 
geneetilisi tekkepõhjusi (deletsioon, UPD, ID). Täiendavad geneetilised analüü-
sid on vajalikud korrektseks diagnoosiks, millel põhineb perekondade nõusta-
mine ja sündroomi kordusriski hindamine. 
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 Mõlema sündroomi levimust on pikka aega hinnatud sarnaseks, umbes 1:10 
000 kuni 1:15 000 kohta (Nicholls jt., 1998; Cassidy jt., 2000), kuid siiani on 
nende sündroomide levimust uuritud eraldi ja erinevatel rahvastikel (Burd jt., 
1990; Åkefeldt jt., 1991; Clayton-Smith, 1993a; Ehara jt., 1995; Kyllerman, 
1995; Petersen jt., 1995; Buckley jt., 1998; Whittington jt., 2001). Täna-
päevaseid molekulaargeneetilisi diagnoosimismeetodeid kasutades on uuritud 
üksnes PWS levimust (Smith jt., 2003; Vogels jt. 2004). AS ja PWS klassi-
kaline kliiniline pilt kujuneb välja teiseks-kolmandaks eluaastaks (Fryburg jt., 
1991; Clayton-Smith, 1993c; Williams jt., 1995; Smith jt., 1996), harva on 
õnnestunud jõuda õige diagnoosini esimesel eluaastal (Hoefnagel jt., 1967; 
Greenberg jt., 1987; Chitayat jt., 1989; Aughton ja Cassidy, 1990; Miller jt., 
1999). Samas on mõlema sündroomi korral hilisem elukvaliteet oluliselt mõju-
tatud varakult rakendatud arendusravist ja PWS korral dieedist. Hiljuti 
ulatuslikku rakendust leidnud kasvuhormoonravi ja järjestikku avaldatud 
surmajuhtude kirjeldused on tõstatanud küsimuse PWS-ga laste äkksurmadest 
ning surmade seotusest kasvuhormooni kasutamisega (Schrander-Stumpel jt., 
2004; Stevenson jt., 2004; Nagai jt., 2005). 
 Levimuse ja haigusega/sündroomiga kaasuvate tervise- ja arenguproblee-
mide uurimine võimaldab hinnata meditsiini- ja sotsiaalsüsteemi vajadusi, 
planeerida ja koordineerida kahe süsteemi omavahelist koostööd ning seeläbi 
parandada konkreetsete haigete elukvaliteeti ja vähendada perekondade stressi. 
 
 
Uuringu eesmärgid 
 
1.  Uurida Eestis AS ja PWS levimust aastatel 1984–2004 elusalt sündinud laste 
hulgas. 
2.  Määrata kõigil AS ja PWS patsientidel sündroomi geneetiline tekkepõhjus. 
3.  Leida kliinilisi sümptomeid, mis võimaldaksid mõlema sündroomi varajast 
avastamist. 
4.  Kirjeldada mõlema sündroomiga patsientide kliinilist pilti. 
5.  Võimalusel uurida mõlema sündroomiga patsientide surma põhjusi. 
 
 
Uurimisgrupid ja uurimismeetodid 
 
Aastatel 2000–2004 toimus kogu Eestit hõlmav retrospektiivne ja prospektiivne 
epidemioloogiline uuring, mille käigus uuriti 1 päeva kuni 18 aasta vanuseid 
Tartu ja Tallinna lastehaiglasse ning Tartusse ja Tallinna geneetilisele konsultat-
sioonile pöördunud AS ja PWS kahtlusega patsiente. Retrospektiivse grupi 
(1984.–1999.a. sündinud) moodustasid patsiendid, kes olid selekteeritud vasta-
valt AS (Williams jt., 1995) ja PWS (Holm jt., 1993) diagnostilistele konsensus-
kriteeriumidele. Lisaks külastasime 2002.a. jooksul kõiki Eesti puuetega laste 
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lastekodusid ja õppeasutusi (28 asutust 1298 elanikuga). Prospektiivse grupi 
(2000.–2004.a. sündinud) moodustasid lapsed, kellel kasutati lihtsustatud 
valikukriteeriume: uuringusse arvati kõik lapsed ebaselge arengupeetuse, lihas-
toonuse muutuste ja/või krambisündroomiga. Kõigilt selekteeritud uuringu-
alustelt võeti 2–5 ml verd DNA metülatsioonitestiks. Kõik positiivse DNA 
metülatsioonitestiga patsiendid läbisid kliinilise uurimise TÜH Lastekliinikus, 
kus igal AS kahtlusega patsiendil tehti EEG ja igal PWS kahtlusega patsiendil 
ENMG, kõigile DNA positiivse metülatsioonitestiga patsientidele tehti vere- ja 
uriinianalüüs, EKG, MRI/CT, kõhuorganite ultraheliuuring ja karpogramm. 
Kõik selekteeritud patsiendid läbisid lasteneuroloogi, oftalmoloogi ja otorino-
larüngoloogi konsultatsiooni, füsioterapeutilise ning psühholoogilise testimise. 
Sündroomi geneetilise etioloogia väljaselgitamiseks teostati kõigil positiivse 
DNA metülatsioonitestiga patsientidel järgnevalt FISH ja kromosoomianalüüs, 
FISH negatiivseid patsiente uuriti edasi uniparentaalse disoomia suhtes. 
Negatiivse DNA metülatsioonitestiga, kuid kliiniliselt AS-ga patsientide DNA 
saadeti UBE3A geeni mutatsiooni uuringule. Levimusandmete arvutamiseks 
kasutati Statistikaameti andmeid seisuga 1. jaanuar 2005.a. 
 
 
Uuringu peamised tulemused 
 
1.   AS minimaalne levimusmäär elussündide hulgas aastatel 1984–2004 oli 
1:52,181 (95% CI 1:25,326–1:129,785) ja levimuspäeval, 1. jaanuaril 
2005.a. oli AS levimusmäär (6 levijuhtu) kuni kahekümneaastaste isikute 
hulgas 1:56,112 (95% CI 1:25,780–1:152,899). 
 
2.   PWS minimaalne levimusmäär elussündide hulgas aastatel 1984–2004 oli 
1:30,439 (95% CI 1:17,425–1:58,908) ja levimuspäeval, 1. jaanuaril 2005.a. 
oli PWS levimusmäär (11 levijuhtu) kuni kahekümneaastaste isikute hulgas 
1:30,606 (95% CI 1:17,105–1:61,311). 
 
3.   Meie uuring näitas, et elussündide hulgas oli AS levimusmäär 1,7 korda 
väiksem kui PWS. Eelnevalt läbi viidud uuringute põhjal arvati, et mõlemad 
sündroomid on võrdselt levinud. 
 
4.   AS statistiliselt eeldatav levimus tõusis 0,88 juhult 100 000 elussünni kohta 
1984. aastal 4,23 juhuni 2004. aastal (muutus on statistiliselt mitteoluline, 
p=0,2). PWS eeldatav levimus tõusis 1,13 juhult 100 000 elussünni kohta 
1984. aastal 7,97 juhuni 2004. aastal (statistiliselt oluline muutus, p=0,032). 
 
5.   Geneetiliste uuringutega kinnitus seitsmest AS-ga patsiendist 15q11-13 
deletsioon kuuel patsiendil (86%) ja UPD15 ühel patsiendil (14%). Kuuel 
PWS-ga patsiendil oli tegemist UPD15 (50%), neljal patsiendil (33%) oli 
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15q11-13 deletsioon sündroomi põhjuseks ja kahel patsiendil (17%) oli 
põhjuseks kromosomaalne translokatsioon –ühel patsiendil oli Robertsoni 
translokatsioon 15;15 ja teisel patsiendil oli tasakaalustamata translokatsioon 
karüotüübiga 45,XX,der(14)t(14;15)(p11;q13).ish der(14)t(14;15) (D14Z1/ 
D22Z1+,D15Z1-,SNRPN-,bac463i22/AQ634845-,PML+,yac895h10+). 
 
6.  PWS-ga vastsündinute kliiniline uurimine näitas, et väljendunud tsentraalse 
lihashüpotoonia, häirunud ärkveloleku, söömise vastu huvi puudumise, 
mööduva bradükardia ja termolabiilsuse, teatud nahanähtude, iseloomulike 
näojoonte ja omapärase pöidla hoiaku koosesinemine ajalisel vastsündinul 
on sümptomkompleks, mille puhul on näidustatud esmase diagnostilise 
uuringuna DNA metülatsioonitest PWS-le. 
 
7.   Meie uuringus oli laste keskmine vanus AS-i diagnoosimisel 6,1 aastat ja 
PWS-i diagnoosimisel 4,3 aastat. AS varane diagnoosimine on komplit-
seeritud spetsiifiliste, imikueas avalduvate sümptomite puudumise tõttu. 
 
8.   Meie patsientide kliiniline fenotüüp lapseeas ei erinenud oluliselt eelnevalt 
kirjeldatud AS ja PWS patsientide omast. Üllatuslik oli sage (67%) aju-
muutuste ja kardiaalsete probleemide esinemine PWS-ga patsientidel. Üle 
ühe aasta vanuste patsientide hulgas täheldasime häirunud luusüsteemi 
küpsemist 57% AS-ga ja 67% PWS-ga lastel. 
 
9.   Meie uuringugrupis esines 21% patsientidest terviseprobleeme, mida pole 
seostatuna AS-ga või PWS-ga eelnevalt kirjeldatud. Ühel AS-ga tüdrukul 
esinesid väga väljendunud luumuutused, ühel PWS-ga poisil diagnoosisime 
X-liitelise ihtüoosi, ühel tüdrukul tasakaalustamata 14;15 translokatsiooniga 
ning 15p13-q13 deletsiooniga oli PWS sümptomatoloogia eriti väljendunud 
ning esinesid ka mitmed lisasümptomid, üks tüdruk AS-ga suri Reye 
sündroomile sarnaselt kulgeva ägeda haigestumise tõttu. 
 
10. Lapseea surma esines meie AS ja PWS patsientide grupis kahel juhul: üks 
tüdruk PWS-ga elas läbi ootamatu varahommikuse südameseiskuse tavali-
selt kulgeva ägeda respiratoorse haigestumise foonil ning suri hiljem 
teadvusele tulemata; üks tüdruk AS-ga suri Reye sündroomile sarnase ägeda 
haigestumise tõttu. 
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